Carcinoma, Non-Small-Cell Lung
Conditions
Keywords
Non-Small-Cell Lung Carcinoma, NSCLC, non small cell lung cancer, non-small cell lung cancer, BRAF mutation, BRAF V600e, BRAF, B-RAF NSCLC, lung cancer, immunotherapy, sasanlimab, encorafenib, binimetinib, axitinib, SEA-TGT, TIGIT, locally advanced, metastatic, ECOG 0, ECOG 1, Stage 3B, Stage IV, previously untreated, second-line therapy, first-line therapy
Brief summary
Phase 1b/Phase 2 Umbrella Study; open-label, multi-center, parallel group study. Sasanlimab (a PD-1 antagonist monoclonal antibody) will be combined with a different targeted therapy in each sub-study. Phase1b of each sub-study will evaluate the safety of the combination and select the dose for the Phase 2 portion. Phase 2 of each sub-study will evaluate the anti-tumor activity of the combination. Sub-Study A is active, not recruiting, ongoing participants are still receiving treatment in Phase 1, Phase 2 will not be initiated. Sub-study B is complete. All participants have discontinued treatment and any additional follow up required by protocol.
Detailed description
Landscape 1011 is a clinical research study for people with advanced (stage 3b or 4) non-small cell lung cancer (NSCLC). The purpose of this study is to learn if the study medicine (sasanlimab, a type of immunotherapy) along with other study medicines is safe and effective in people with non-small cell lung cancer that has spread outside of the lungs. There are currently two sub-studies using different types of medicines. People in the first sub-study will receive sasanlimab as a subcutaneous (under the skin) injection at the study clinic every 4 weeks. Additionally, they will take targeted cancer therapies encorafenib by mouth once a day and binimetinib by mouth twice a day at home. People in the second sub-study will receive the study medicine sasanlimab as a subcutaneous (under the skin) injection at the study clinic every 3 weeks and will also receive SEA-TGT (an immunotherapy) by infusion every three weeks. Additionally, they will take axitinib (a targeted therapy) by mouth twice a day at home. In addition to taking the study drugs, participants in the sub-studies will be asked to visit the clinic for health checks. These include health questions, physical examinations, blood and urine samples, and imaging scans. These assessments help the study doctor and team to monitor the participants' safety and well-being, and to see how their cancer is responding to the treatment. Participants will continue in the study until the cancer is no longer responding to the study medicine.
Interventions
DRUGSasanlimab Prefilled syringe
prefilled syringe
DRUGEncorafenib
capsules
DRUGBinimetinib
tablets
DRUGSasanlimab
solution supplied in vials
DRUGAxitinib
tablets
DRUGSEA-TGT
solution in vials
Sponsors
Pfizer
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Umbrella Phase 1b & 2: * Histologically or cytologically confirmed locally advanced/metastatic (Stage IIIB-IV) NSCLC. * At least one measurable lesion per RECIST v1.1 at Screening. * ECOG Performance Status 0 or 1. * Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade ≤1. * Adequate hepatic, renal, and bone marrow function. Additional Inclusion Criteria for Sub-Study A Phase 1b &2: -BRAFV600E mutation in tumor tissue or plasma as determined by a local laboratory PCR or NGS assay and documented in a local pathology report. Additional Inclusion Criteria for Sub-Study A Phase 1b only: -Any line of therapy for locally advanced/metastatic NSCLC. Additional Inclusion Criteria for Sub-Study A Phase 2 only: -Previously untreated for locally advanced/metastatic NSCLC Additional Inclusion Criteria for Sub-Study B Phase 1b only:: -Any line of therapy for locally advanced/metastatic NSCLC. Additional Inclusion Criteria for Sub-Study B Phase 2 only: * Previously untreated for locally advanced/metastatic NSCLC (Arms B1 & B2), or * One or 2 prior lines of therapy for advanced/metastatic NSCLC (Arm B3), including immune checkpoint inhibitor treatment + chemotherapy, and have progressed during or after that therapy. * PD-L1 TPS ≥1%
Exclusion criteria
Umbrella Phase 1b &2: * Active or prior autoimmune disease that might deteriorate when receiving an immunostimulatory agent. * Active non-infectious pneumonitis, pulmonary fibrosis, or known history of immune-mediated pneumonitis. * Active infection requiring systemic therapy. * Clinically significant cardiovascular disease. * Other malignancy within 2 years of first dose, with exceptions. * Symptomatic brain metastasis, with exceptions. Additional
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Phase 1b of Sub-Study A: Percentage of Participants With Dose-Limiting Toxicities (DLT) | Day 1 up to Day 28 of Cycle 1 | DLT=AEs in DLT observation period (OP) related to any study intervention:Grade (G)4 neutropenia;thrombocytopenia or anemia;febrile neutropenia;neutropenic infection;G3 thrombocytopenia with bleeding. Any G\>=3 toxicity (except transient G3 fatigue, local reactions/headache that resolved to G\<=1/baseline; G3 nausea, vomiting controlled within 72 hrs, G3 hypertension controlled by medical therapy (MT), G3 diarrhea that improved to G\<=2 within 72 hrs, G3 skin toxicity that resolved to G\<=1 in \<7 days after MT, G3 endocrinopathies controlled by MT and tumors flare); Non-hematologic G3 lab abnormality \[LA\](medical intervention or hospitalization), or any G4 LA;ALT/AST\>3\*ULN (normal at baseline) or \>3\*ULN and doubling baseline (\>ULN at baseline) and associated with total bilirubin(TB) \>2\*ULN;or ALT/AST\>5\*ULN; or TB\>3\*ULN. Missing 75% of planned doses during DLT OP due to treatment-related toxicities. AE not listed/DLT criteria outside DLT OP was DLT at discretion of sponsor and investigator. |
| Phase 2 of Sub-Study A: Durable Objective Response Rate (ORR) | From the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy | Durable ORR was defined as percentage of participants with confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 based on investigator assessment, lasting for at least 10 months from the date of first CR or PR until the date of the first documentation of disease progression (PD), death, or start of new anticancer therapy. CR was defined as complete disappearance of all target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 millimeter \[mm\]). PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. PD was defined as 20% increase in sum of diameters of target measurable lesions above smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm. |
| Phase 1b of Sub-Study B: Percentage of Participants With DLT | Day 1 up to Day 21 of Cycle 1 | DLT=AEs in DLT OP related to any study intervention: G4 neutropenia; thrombocytopenia or anemia; neutropenia; neutropenic infection; G3 thrombocytopenia with bleeding. Any G\>=3 toxicity (except transient G3 fatigue, local reactions/headache that resolved to G\<=1/baseline; G3 nausea, vomiting controlled within 72 hrs, G3 hypertension controlled by MT, G3 diarrhea that improved to G\<=2 within 72 hrs, G3 skin toxicity that resolved to G\<=1 in \<7 days after MT, G3 endocrinopathies controlled by MT and tumors flare); Non-hematologic G3 LA (medical intervention or hospitalization), or any G4 LA;ALT/AST\>3\*ULN (normal at baseline) or \>3\*ULN and doubling baseline (\>ULN at baseline) and associated with TB \>2\*ULN; or ALT/AST\>5\*ULN; or TB\>3\*ULN. Missing 75% of planned doses during DLT OP due to treatment-related toxicities. AE not listed/DLT criteria outside DLT OP was DLT at discretion of sponsor and investigator. |
| Phase 2 Sub-Study B: Objective Response Rate | From the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy (maximum of 21 months) | ORR was defined as percentage of participants with confirmed CR or PR according to RECIST v1.1 based on investigator assessment, from the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy. CR was defined as complete disappearance of all target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 millimeter \[mm\]). PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. PD was defined as 20% increase in sum of diameters of target measurable lesions above smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Phase 1b of Sub-Study A: Area Under the Concentration Versus Time Curve Over the Dosing Interval (AUCtau) After Single Dose of Sasanlimab | Cycle 1 (pre-dose on Day 1, 168 hours [Day 8] and 336 hours [Day 15] and Day 28 post-dose) (1 cycle= 28 days) | AUCtau was defined as area under the plasma concentration time curve from time zero to the next dose. |
| Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment (maximum exposure = 38.66 months; maximum follow-up approximately 39.66 months) | Chemistry parameters included: alanine aminotransferase (ALT) increase, alkaline phosphatase (ALP) increased, aspartate aminotransferase (AST) increased, blood bilirubin increased, creatinine phosphokinase (CPK) increased, chronic kidney disease (CKD), creatinine increased, hypercalcemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia, lipase increased, serum amylase increased. Chemistry abnormalities were graded as per NCI- CTCAE v 5.0 where, grade(G) 0= non-missing lab value that does not meet either of G1 through 4 criteria, G1=mild, G2=moderate, G3=severe and G4= life-threatening or disabling. Baseline is defined as the last assessment prior to the date/time of the first dose of study treatment. Number of participants with shift from baseline in hematology parameters by grades (as per CTCAE version 5.0) were reported. |
| Phase 2 of Sub-Study A: Number of Participants With Laboratory Abnormalities | From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment | Hematology and clinical chemistry parameters were planned to be assessed. |
| Phase 1b of Sub-Study A: Durable Objective Response Rate (ORR) | From the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy (approximately 38.66 months) | Durable ORR was defined as percentage of participants with confirmed CR or PR according to RECIST v1.1 based on investigator assessment, lasting for at least 10 months from the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy. CR was defined as complete disappearance of all target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 milli meter \[mm\]). PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. PD was defined as 20% increase in sum of diameters of target measurable lesions above smallest sum observed (over baseline if no decrease in the sum is observed during therapy) with a minimum absolute increase of 5 mm. Non-CR/Non-PD: Persistence of any non-target lesions and/or tumor marker level (if being followed) above the normal limits. |
| Phase 1b of Sub-Study A: Objective Response Rate | From the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy (approximately 38.66 months) | Objective response rate is defined as percentage of participants with confirmed best overall response of CR or PR according to RECIST v1.1 from the date of first dose of study treatment until the date of the first documentation of PD. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. PD was defined as 20% increase in sum of diameters of target measurable lesions above smallest sum observed (over baseline if no decrease in the sum is observed during therapy) with a minimum absolute increase of 5 mm. Non-CR/Non-PD: Persistence of any non-target lesions and/or tumor marker level (if being followed) above the normal limits. |
| Phase 2 of Sub-Study A: Objective Response Rate | From the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy | Objective response (OR) rate is defined as percentage of participants with confirmed best overall response of CR or PR according to RECIST v1.1 from the date of first dose of study treatment until the date of the first documentation of PD. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. |
| Phase 2 of Sub-Study A: Duration of Response (DR) | From the date of first documentation of OR to the date of the first documentation of PD or death due to any cause, whichever occurred first | DR was defined for participants with confirmed OR as time from date of first documentation of OR to the date of first documentation of PD or death (any cause), whichever occurred first. OR=CR or PR according to RECIST v1.1 based on investigator assessment. CR and PR must be confirmed by repeat assessments performed no \<4 weeks after criteria for response were first met. CR=complete disappearance of all target lesions (TLs) with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). PR=greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions (TMLs). PD=20% increase in sum of diameters of TMLs above smallest sum observed (over baseline if no decrease in sum was observed during therapy), with a minimum absolute increase of 5 mm. |
| Phase 2 of Sub-Study A: Time to Tumor Response (TTR) | From the date of first dose of study treatment to the date of first documentation of objective response | TTR is defined for participants with confirmed objective response as the time from the date of first dose of study treatment to the date of first documentation of objective response (CR or PR) which was subsequently confirmed. CR=complete disappearance of all target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). PR=greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. |
| Phase 2 of Sub-Study A: Progression-Free Survival (PFS) | From the date of first dose of study treatment to the date of first documentation of PD or death due to any cause, whichever occurred first | PFS is defined as the time from the date of first dose of study treatment to the date of first documentation of PD or death due to any cause, whichever occurred first. PD=20% increase in sum of diameters of target measurable lesions above smallest sum observed (over baseline if no decrease in sum was observed during therapy), with a minimum absolute increase of 5 mm. |
| Phase 2 of Sub-Study A: Area Under the Concentration Versus Time Curve Over the Dosing Interval (AUCtau) After Single Dose of Sasanlimab | Cycle 1 (pre-dose on Day 1, 336 hours [Day 15] and Day 28 post-dose) (1 cycle= 28 days) | — |
| Phase 1b of Sub-Study A: Maximum Observed Plasma Concentration (Cmax) of Sasanlimab | Cycle 1 (pre-dose on Day 1, 168 hours [Day 8],336 hours [Day 15] and Day 28 post-dose) and Cycle 5 (pre-dose on Day 1 and 168 hours [Day 8] post dose) (1 cycle= 28 days) | — |
| Phase 2 of Sub-Study A: Maximum Observed Plasma Concentration (Cmax) of Sasanlimab | Cycle 1 (pre-dose on Day 1, 336 hours [Day 15] and Day 28 post-dose) and Cycle 5 Day 1 (pre-dose) (1 cycle= 28 days) | — |
| Phase 1b of Sub-Study A: Time for Cmax (Tmax) of Sasanlimab | Cycle 1 (pre-dose on Day 1, 168 hours [Day 8], 336 hours [Day 15] and Day 28 post-dose) and Cycle 5 (pre-dose on Day 1 and 168 hours [Day 8] post dose) (1 cycle= 28 days) | — |
| Phase 2 of Sub-Study A: Time for Cmax (Tmax) of Sasanlimab | Cycle 1 (pre-dose on Day 1, 336 hours [Day 15] and Day 28 post-dose) and Cycle 5 Day 1 (pre-dose) (1 cycle= 28 days) | — |
| Phase 1b of Sub-Study A: Pre-dose Concentration During Multiple Dosing (Ctrough) of Sasanlimab | Cycle 5 Day 1 (pre-dose) (1 cycle= 28 days) | — |
| Phase 2 of Sub-Study A: Pre-dose Concentration During Multiple Dosing (Ctrough) of Sasanlimab | Cycle 5 Day 1 (pre-dose) (1 cycle= 28 days) | — |
| Phase 1b of Sub-Study A: Ctrough of Encorafenib | Day 1 (pre-dose) of Cycle 1, 2 and 5; Day 15 of Cycle 1 (1 cycle= 28 days) | — |
| Phase 2 of Sub-Study A: Ctrough of Encorafenib | Cycle 5 Day 1 (pre-dose) | — |
| Phase 1b of Sub-Study A: Ctrough of Binimetinib | Day 1 (pre-dose) of Cycles 1, 2, and 5 (1 cycle= 28 days) | — |
| Phase 2 of Sub-Study A: Ctrough of Binimetinib | Cycle 5 Day 1 (pre-dose) | — |
| Phase 1b of Sub-Study A: Number of Participants With Positive Anti-Drug Antibody (ADA) and Neutralizing Antibody (NAb) Against Sasanlimab | Pre-dose on Cycle 1 Day 1 until end of treatment (up to approximately 255 days) (1 cycle= 28 days) | In this outcome measure, number of ADA-positive and NAb-positive participants has been presented. A participant was considered ADA (or NAb) positive if (1) baseline titer was missing or negative and participant had \>= 1 post-treatment positive titer (treatment-induced), or (2) positive titer at baseline and had a \>= \[4-fold dilution increase\] in titer (equivalent to 0.602 unit increase in logarithm to base 10 (log10) titer from baseline in \>= 1 post-treatment sample (treatment-boosted). |
| Phase 2 of Sub-Study A: Number of Participants With Positive Anti-Drug Antibody (ADA) and Neutralizing Antibody (NAb) Against Sasanlimab | Pre-dose on Cycle 1 Day 1 until end of treatment | — |
| Phase 2 of Sub-Study A: Objective Response (OR) Rate by Programmed Death Ligand-1 (PD-L1) Expression at Baseline | From the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy | OR rate is defined as percentage of participants with CR or PR according to RECIST v1.1 based on investigator assessment. CR=complete disappearance of all target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). PR=greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. OR by PD-L1 expression at baseline was planned to be assessed. |
| Phase 2 of Sub-Study A: Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (EORTC QLQ-C30) Score | Baseline up to end of treatment | EORTC QLQ-C30: consisted of 30 questions grouped into 5 functional scales (physical, role, cognitive, emotional, and social); a global health status/global quality of life scale; 3 symptom scales (fatigue, pain, nausea and vomiting); and 6 single items that assessed additional symptoms (dyspnea, appetite loss, sleep disturbance, constipation, and diarrhea), and financial impact. All scales and single item measures ranged in score from 0 to 100. Higher scores on the global health status/quality of life scale represent higher health status/quality of life. Higher scores on the functional scales represent higher levels of functioning. Higher scores on the symptom scales and single items represent a greater presence of symptoms or financial impact. |
| Phase 2 of Sub-Study A: Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC), Quality of Life Questionnaire-Lung Cancer 13 (QLQ- LC13) Score | Baseline up to end of treatment | The EORTC QLQ-LC13 is the lung cancer specific module of the EORTC Quality of Life Questionnaire. The EORTC QLQ-LC13 consisted of 13 questions which included 1 multi-item scale and 9 single items assessing symptoms (dyspnea, cough, hemoptysis, and site specific pain), side effects (sore mouth, dysphagia, peripheral neuropathy, and alopecia), and pain medication use. The item scale ranged from 1 to 4 (1 = Not at all; 4 = Very Much) where the EORTC-QLQ-LC13 scoring algorithm was applied to convert to a 0 to 100 point scale where 100 is best quality of life (QOL), for comparability. Higher scores are reflective of a greater presence of symptoms. |
| Phase 1b of Sub-Study B: Number of Participants With Adverse Events Graded According to NCI-CTCAE Version 5.0 | From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment (maximum exposure = 38.66 months; maximum follow-up approximately 39.66 months) | An AE is any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs were graded by the investigator according to NCI CTCAE version 5.0; where Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life-threatening and Grade 5=death. |
| Phase 2 of Sub-Study B: Number of Participants With Adverse Events Graded According to NCI-CTCAE Version 5.0 | From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment (maximum exposure = 38.66 months; maximum follow-up approximately 39.66 months) | An AE is any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs were graded by the investigator according to NCI CTCAE version 5.0; where Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life-threatening and Grade 5=death |
| Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment (maximum exposure = 39.3 months; maximum follow-up approximately 39.66 months) | Hematology parameters included: anemia, hemoglobin increased, leukocytosis, lymphocyte count decreased, lymphocyte count increased, neutrophil count decreased, platelet count decreased, white blood cell decreased. Laboratory abnormalities were graded as per NCI- CTCAE v 5.0 where, grade(G) 0= non-missing lab value that does not meet either of G1 through 4 criteria, G1=mild, G2=moderate, G3=severe and G4= life-threatening or disabling. Baseline is defined as the last assessment prior to the date/time of the first dose of study treatment. Number of participants with shift from baseline in hematology parameters by grades (as per CTCAE version 5.0) were reported. |
| Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment (maximum exposure = 38.66 months; maximum follow-up approximately 39.66 months) | Chemistry parameters included: alanine aminotransferase (ALT) increased, alkaline phosphatase (ALP) increased, aspartate aminotransferase (AST) increased, blood bilirubin increased, creatinine phosphokinase (CPK) increased, chronic kidney disease (CKD), creatinine increased, hypercalcemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia, lipase increased, serum amylase increased. Chemistry abnormalities were graded as per NCI- CTCAE v 5.0 where, grade(G) 0= non-missing lab value that does not meet either of G1 through 4 criteria, G1=mild, G2=moderate, G3=severe and G4= life-threatening or disabling. Baseline is defined as the last assessment prior to the date/time of the first dose of study treatment. Number of participants with shift from baseline in hematology parameters by grades (as per CTCAE version 5.0) were reported. |
| Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment (maximum exposure = 38.66 months; maximum follow-up approximately 39.66 months) | Hematology parameters included: anemia, hemoglobin increased, lymphocyte count decreased, leukocytosis, neutrophil count decreased, platelet count decreased, white blood cell decreased. Number of participants with shift from baseline in hematology parameters by grades as per CTCAE version 5.0 were reported. Grade 0= non-missing lab value that does not meet either of Grade 1 through 4 criteria; Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling. |
| Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment (maximum exposure = 38.66 months; maximum follow-up approximately 39.66 months) | Chemistry parameters included: ALT increased, ALP increased, AST increased, blood bilirubin increased, chronic kidney disease, creatinine increased, hypercalcemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypokalemia, hypomagnesemia, hyponatremia, lipase increased, serum amylase increased. Number of participants with maximum CTCAE V5.0 grade in chemistry parameters were reported. Grade 0= non-missing lab value that does not meet either of Grade 1 through 4 criteria; Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling. |
| Phase 1b of Sub-Study B: Objective Response Rate | From the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy, whichever occurred first (maximum of 21 months) | ORR was defined as percentage of participants with confirmed CR or PR according to RECIST v1.1 based on investigator assessment, from the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy. CR was defined as complete disappearance of all target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. PD was defined as 20% increase in sum of diameters of target measurable lesions above smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm. Two sided 95% CI was based on Clopper-Pearson method. |
| Phase 1b of Sub-Study B: Duration of Response (DR) | From the date of first documentation of OR to the date of first documentation of PD or death, whichever occurred first (maximum of 21 months) | DR was defined for participants with confirmed objective response (OR) as time from date of first documentation of OR to the date of first documentation of PD or death (any cause), whichever occurred first. OR=CR or PR according to RECIST v1.1 based on investigator assessment. CR and PR must be confirmed by repeat assessments performed no \<4 weeks after criteria for response were first met. CR=complete disappearance of all target lesions (TLs) with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). PR=greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions (TMLs). PD=20% increase in sum of diameters of TMLs above smallest sum observed (over baseline if no decrease in sum was observed during therapy), with a minimum absolute increase of 5 mm. |
| Phase 1b of Sub-Study B: Time to Tumor Response (TTR) | From the date of first dose of study treatment to the date of first documentation of objective response (CR or PR) (maximum of 21 months) | TTR is defined for participants with confirmed objective response as the time from the date of first dose of study treatment to the date of first documentation of objective response (CR or PR) which was subsequently confirmed. CR=complete disappearance of all target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). PR=greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. |
| Phase 1b of Sub-Study B: Progression-Free Survival (PFS) | From the date of first dose of study treatment to the date of first documentation of PD or death due to any cause, whichever occurred first (maximum of 21 months) | PFS is defined as the time from the date of first dose of study treatment to the date of first documentation of PD or death due to any cause, whichever occurred first. PD=20% increase in sum of diameters of target measurable lesions above smallest sum observed (over baseline if no decrease in sum was observed during therapy), with a minimum absolute increase of 5 mm. |
| Phase 2 of Sub-Study B: Duration of Response (DR) | From date of first documentation of OR to the date of first documentation of PD or death, whichever occurred first (maximum of 21 months) | DR was defined for participants with confirmed OR as time from date of first documentation of OR to the date of first documentation of PD or death (any cause), whichever occurred first. OR=CR or PR according to RECIST v1.1 based on investigator assessment. CR and PR must be confirmed by repeat assessments performed no \<4 weeks after criteria for response were first met. CR=complete disappearance of all target lesions (TLs) with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). PR=greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions (TMLs). PD=20% increase in sum of diameters of TMLs above smallest sum observed (over baseline if no decrease in sum was observed during therapy), with a minimum absolute increase of 5 mm. |
| Phase 2 of Sub-Study B: Time to Tumor Response (TTR) | From the date of first dose of study treatment to the date of first documentation of objective response (CR or PR) (maximum of 21 months) | TTR is defined for participants with confirmed OR as the time from the date of first dose of study treatment to the date of first documentation of objective response (CR or PR) which was subsequently confirmed. CR=complete disappearance of all target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). PR=greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. |
| Phase 2 of Sub-Study B: Progression-Free Survival (PFS) | From the date of first dose of study treatment to the date of first documentation of PD or death due to any cause, whichever occurred first (maximum of 21 months) | PFS is defined as the time from the date of first dose of study treatment to the date of first documentation of PD or death due to any cause, whichever occurred first. PD=20% increase in sum of diameters of target measurable lesions above smallest sum observed (over baseline if no decrease in sum was observed during therapy), with a minimum absolute increase of 5 mm. |
| Phase 2 of Sub-Study B: Overall Survival (OS) | From the date of first dose of study treatment to the date of death due to any cause or censoring date, whichever occurred first (maximum of 21 months) | OS is defined as the time from the date of first dose of study treatment to the date of death due to any cause. Participants last known to be alive were planned to be censored at the date of last contact. |
| Phase 1b of Sub-Study B: Cmax of Sasanlimab | Cycle 1: pre-dose, 168 hours post-dose on Day 1, Cycle 5: pre-dose, 168 hours post-dose on Day 1 (1 cycle= 21 days) | — |
| Phase 1b of Sub-Study B: Cmax of Axitinib | Cycle 1: pre-dose on Day 1, Day 8 and 3 hours post-dose on Day 1; Cycle 5: pre-dose on Day 1, Day 8 and 3 hours post-dose on Day 1 (1 cycle= 21 days) | — |
| Phase 1b of Sub-Study B: Cmax of SEA-TGT | Cycle 1: pre-dose, 168 hours post-dose on Day 1, Cycle 5: pre-dose, 168 hours post-dose on Day 1 (1 cycle= 21 days) | — |
| Phase 2 of Sub-Study B: Cmax of Sasanlimab | Cycle 1: pre-dose, 168 hours post-dose on Day 1, Cycle 5: pre-dose, 168 hours post-dose on Day 1 (1 cycle= 21 days) | — |
| Phase 2 of Sub-Study B: Cmax of Axitinib | Cycle 1: pre-dose on Day 1, Day 8 and 3 hours post-dose on Day 1; Cycle 5: pre-dose on Day 1, Day 8 and 3 hours post-dose on Day 1 (1 cycle= 21 days) | — |
| Phase 2 of Sub-Study B: Cmax of SEA-TGT | Cycle 1: pre-dose, 168 hours post-dose on Day 1, Cycle 5: pre-dose, 168 hours post-dose on Day 1 (1 cycle= 21 days) | — |
| Phase 1b of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of Sasanlimab | Pre-dose on Cycle 1 Day 1 and Cycle 5 Day 1 (1 cycle= 21 days) | — |
| Phase 1b of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of Axitinib | Pre-dose on Cycle 1 Day 1 and Day 8; pre-dose on Cycle 5 Day 1 and Day 8 (1 cycle= 21 days) | — |
| Phase 1b of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of SEA-TGT | Pre-dose on Cycle 1 Day 1; pre-dose on Cycle 5 Day 1 (1 cycle= 21 days) | — |
| Phase 2 of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of Sasanlimab | Cycle 1: pre-dose on Day 1, Cycle 5: pre-dose on Day 1 (1 cycle= 21 days) | — |
| Phase 2 of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of Axitinib | Pre-dose on Cycle 1 Day 1 and Day 8; pre-dose on Cycle 5 Day 1 and Day 8 (1 cycle= 21 days) | — |
| Phase 1b of Sub-Study A: Number of Participants With Adverse Events (AEs) Graded According to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 | From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment (maximum exposure = 38.66 months; maximum follow-up approximately 39.66 months) | An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs was graded by the investigator according to NCI CTCAE grade 1 to 5 version 5.0; where Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life-threatening and Grade 5=death. |
| Phase 1b of Sub-Study B: Number of Participants With Positive Anti-Drug Antibody (ADA) Against Sasanlimab and SEA-TGT | Pre-dose on Cycle 1 Day 1 until end of treatment (up to approximately 21 months) (1 cycle= 21 days) | A participant was considered ADA (or NAb) positive if (1) baseline titer was missing or negative and participant had \>= 1 post-treatment positive titer (treatment-induced), or (2) positive titer at baseline and had a \>= \[4-fold dilution increase\] in titer (equivalent to 0.602 unit increase in logarithm to base 10 (log10) titer from baseline in \>= 1 post-treatment sample (treatment-boosted). |
| Phase 2 of Sub-Study B: Number of Participants With Positive Anti-Drug Antibody (ADA) Against Sasanlimab and SEA-TGT | Pre-dose on Cycle 1 Day 1 until end of treatment (up to approximately 21 months) (1 cycle= 21 days) | — |
| Phase 2 of Sub-Study B: Objective Response Rate by PD-L1 Expression in Available Tumor Tissue | From the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy (maximum of 21 months) | ORR was defined as percentage of participants with confirmed CR or PR according to RECIST v1.1 based on investigator assessment, from the date of first CR or PR until the date of the first documentation of disease progression (PD), death, or start of new anticancer therapy. CR was defined as complete disappearance of all target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 millimeter \[mm\]). PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. PD was defined as 20% increase in sum of diameters of target measurable lesions above smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm. |
| Phase 2 of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of SEA-TGT | Pre-dose on Cycle 1 Day 1; pre-dose on Cycle 5 Day 1 (1 cycle= 21 days) | — |
| Phase 2 of Sub-Study A: Number of Participants With Adverse Events Graded According to NCI-CTCAE Version 5.0 | From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment | An AE is any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs were planned to be graded by the investigator according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version (v) 5.0; where Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life-threatening and Grade 5=death. |
| Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment (maximum exposure = 38.66 months; maximum follow-up approximately 39.66 months) | Hematology parameters included: anemia, hemoglobin increased, leukocytosis, lymphocyte count decreased, lymphocyte count increased, leukocytosis, neutrophil count decreased, platelet count decreased, white blood cell decreased. Laboratory abnormalities were graded as per NCI- CTCAE v 5.0 where, grade(G) 0= non-missing lab value that does not meet either of G1 through 4 criteria, G1=mild, G2=moderate, G3=severe and G4= life-threatening or disabling. Baseline is defined as the last assessment prior to the date/time of the first dose of study treatment. Number of participants with shift from baseline in hematology parameters by grades (as per CTCAE version 5.0) were reported. |
| Phase 2 of Sub-Study A: Overall Survival (OS) | From the date of first dose of study treatment to the date of death due to any cause or censoring date | OS is defined as the time from the date of first dose of study treatment to the date of death due to any cause. Participants last known to be alive were planned to be censored at the date of last contact. |
Countries
Australia, Belgium, Taiwan, United States
Participant flow
Recruitment details
Sub-study A (SSA) was planned to be conducted in 2 parts: Phase 1b and Phase 2. Due to a business decision, Phase 2 was not initiated, hence no participants were enrolled for Phase 2 of SSA. Sub-study B (SSB) was conducted in 2 parts: Phase 1b and Phase 2.
Pre-assignment details
57 participants signed informed consent and 34 participants were enrolled in the study. Of these 34 participants, 13 were enrolled in Sub-study A and 21 in Sub-study B (9 in Phase \[Ph\] 1b and 12 in Phase 2).
Participants by arm
| Arm | Count |
|---|---|
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) Participants with NSCLC with BRAFV600 mutations were administered a single dose of sasanlimab 300 mg subcutaneously on Day 1 of each cycle along with QD oral dose of 300 mg encorafenib and BID oral dose of 45 mg binimetinib during each 28-day cycle. | 4 |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) Participants with NSCLC with BRAFV600 mutations were administered a single dose of sasanlimab 300 mg subcutaneously on Day 1 of each cycle along with QD oral dose of 450 mg encorafenib and BID oral dose of 45 mg binimetinib during each 28-day cycle. | 9 |
| Phase 1b of SSB: Sasanlimab (225 mg) + Axitinib (5 mg) Participants with NSCLC and who received any line of therapy for advanced/metastatic NSCLC were administered a single dose of sasanlimab 225 mg Q3W subcutaneously along with BID oral dose of 5 mg axitinib on Day 1 of each cycle during each 21-day cycle. | 3 |
| Phase 1b of SSB: Sasanlimab (225mg) + Axitinib (5 mg) + SEA-TGT(1mg/kg) Participants with NSCLC and who received any line of therapy for advanced/metastatic NSCLC were administered a single dose of sasanlimab 225 mg Q3W subcutaneously along with BID oral dose of 5 mg axitinib on Day 1 of each cycle and Q3W IV infusion of 1 mg/kg SEA-TGT on Day 1 of each cycle during each 21-day cycle. | 6 |
| Phase 2 of SSB: 1L NSCLC PD-L1: TPS 1-49% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) Participants with NSCLC with who were treatment-naïve for advanced/metastatic disease with low PD-L1 levels TPS-49 % were administered a single dose of sasanlimab 225 mg Q3W subcutaneously along with BID oral dose of 5 mg axitinib on Day 1 of each cycle and Q3W IV infusion of 1 mg/kg SEA-TGT on Day 1 of each cycle during each 21-day cycle. | 3 |
| Phase 2 of SSB: 1L NSCLC / PD-L1: TPS >=50% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) Participants with NSCLC with who were treatment-naïve for advanced/metastatic disease with high PD-L1 (TPS \>=50%) were administered a single dose of sasanlimab 225 mg Q3W subcutaneously along with BID oral dose of 5 mg axitinib on Day 1 of each cycle and Q3W IV infusion of 1 mg/kg SEA+ TGT on Day 1 of each cycle during each 21-day cycle. | 2 |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) Participants with NSCLC who received 1 or 2 lines of therapy for advanced/metastatic NSCLC and whose disease has progressed on prior PD-1/ PD-L1 therapy and who have PD-L1 TPS \>= 1% were administered a single dose of sasanlimab 225 mg Q3W subcutaneously along with BID oral dose of 5 mg axitinib on Day 1 of each cycle and 1 mg/kg IV infusion Q3W SEA-TGT on Day 1 of each cycle during each 21-day cycle. | 7 |
| Total | 34 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 | FG006 |
|---|---|---|---|---|---|---|---|---|
| Sub-study A- Follow-up Phase | Death | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Sub-study A- Follow-up Phase | Study terminated by sponsor | 1 | 3 | 0 | 0 | 0 | 0 | 0 |
| Sub-study A- Treatment Phase | Adverse Event | 1 | 4 | 0 | 0 | 0 | 0 | 0 |
| Sub-study A- Treatment Phase | Death | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
| Sub-study A- Treatment Phase | Global deterioration of health status | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Sub-study A- Treatment Phase | Other | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sub-study A- Treatment Phase | Progressive disease | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Sub-study A- Treatment Phase | Study terminated by sponsor | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Sub-study A- Treatment Phase | Withdrawal by Subject | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sub-study B- Follow-up Phase | Death | 0 | 0 | 1 | 3 | 1 | 0 | 3 |
| Sub-study B- Follow-up Phase | Study terminated by sponsor | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Sub-study B- Treatment Phase | Adverse Event | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Sub-study B- Treatment Phase | Death | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Sub-study B- Treatment Phase | Global deterioration of health status | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Sub-study B- Treatment Phase | Physician Decision | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Sub-study B- Treatment Phase | Progressive disease | 0 | 0 | 3 | 2 | 2 | 1 | 5 |
| Sub-study B- Treatment Phase | Withdrawal by Subject | 0 | 0 | 0 | 1 | 0 | 1 | 0 |
Baseline characteristics
| Characteristic | Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of SSB: Sasanlimab (225 mg) + Axitinib (5 mg) | Phase 1b of SSB: Sasanlimab (225mg) + Axitinib (5 mg) + SEA-TGT(1mg/kg) | Phase 2 of SSB: 1L NSCLC PD-L1: TPS 1-49% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of SSB: 1L NSCLC / PD-L1: TPS >=50% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Total |
|---|---|---|---|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 3 Participants | 4 Participants | 3 Participants | 5 Participants | 2 Participants | 2 Participants | 2 Participants | 21 Participants |
| Age, Categorical Between 18 and 65 years | 1 Participants | 5 Participants | 0 Participants | 1 Participants | 1 Participants | 0 Participants | 5 Participants | 13 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 2 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 4 Participants | 8 Participants | 3 Participants | 6 Participants | 3 Participants | 2 Participants | 6 Participants | 32 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants | 5 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 7 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants | 0 Participants | 0 Participants | 2 Participants | 1 Participants | 0 Participants | 0 Participants | 4 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 2 Participants | 4 Participants | 3 Participants | 3 Participants | 2 Participants | 2 Participants | 7 Participants | 23 Participants |
| Sex: Female, Male Female | 3 Participants | 3 Participants | 1 Participants | 1 Participants | 1 Participants | 1 Participants | 2 Participants | 12 Participants |
| Sex: Female, Male Male | 1 Participants | 6 Participants | 2 Participants | 5 Participants | 2 Participants | 1 Participants | 5 Participants | 22 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk |
|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 4 | 4 / 9 | 1 / 3 | 5 / 6 | 1 / 3 | 0 / 2 | 3 / 7 |
| other Total, other adverse events | 4 / 4 | 9 / 9 | 3 / 3 | 6 / 6 | 3 / 3 | 2 / 2 | 7 / 7 |
| serious Total, serious adverse events | 2 / 4 | 7 / 9 | 1 / 3 | 3 / 6 | 1 / 3 | 0 / 2 | 4 / 7 |
Outcome results
Primary
Phase 1b of Sub-Study A: Percentage of Participants With Dose-Limiting Toxicities (DLT)
DLT=AEs in DLT observation period (OP) related to any study intervention:Grade (G)4 neutropenia;thrombocytopenia or anemia;febrile neutropenia;neutropenic infection;G3 thrombocytopenia with bleeding. Any G\>=3 toxicity (except transient G3 fatigue, local reactions/headache that resolved to G\<=1/baseline; G3 nausea, vomiting controlled within 72 hrs, G3 hypertension controlled by medical therapy (MT), G3 diarrhea that improved to G\<=2 within 72 hrs, G3 skin toxicity that resolved to G\<=1 in \<7 days after MT, G3 endocrinopathies controlled by MT and tumors flare); Non-hematologic G3 lab abnormality \[LA\](medical intervention or hospitalization), or any G4 LA;ALT/AST\>3\*ULN (normal at baseline) or \>3\*ULN and doubling baseline (\>ULN at baseline) and associated with total bilirubin(TB) \>2\*ULN;or ALT/AST\>5\*ULN; or TB\>3\*ULN. Missing 75% of planned doses during DLT OP due to treatment-related toxicities. AE not listed/DLT criteria outside DLT OP was DLT at discretion of sponsor and investigator.
Time frame: Day 1 up to Day 28 of Cycle 1
Population: DLT-evaluable analysis set included all participants who received at least 1 dose of study treatment in Phase 1b and either experienced DLT during the DLT-observation period or completed the DLT-observation period without DLT.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Percentage of Participants With Dose-Limiting Toxicities (DLT) | 0 Percentage of participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Percentage of Participants With Dose-Limiting Toxicities (DLT) | 33.3 Percentage of participants |
Primary
Phase 1b of Sub-Study B: Percentage of Participants With DLT
DLT=AEs in DLT OP related to any study intervention: G4 neutropenia; thrombocytopenia or anemia; neutropenia; neutropenic infection; G3 thrombocytopenia with bleeding. Any G\>=3 toxicity (except transient G3 fatigue, local reactions/headache that resolved to G\<=1/baseline; G3 nausea, vomiting controlled within 72 hrs, G3 hypertension controlled by MT, G3 diarrhea that improved to G\<=2 within 72 hrs, G3 skin toxicity that resolved to G\<=1 in \<7 days after MT, G3 endocrinopathies controlled by MT and tumors flare); Non-hematologic G3 LA (medical intervention or hospitalization), or any G4 LA;ALT/AST\>3\*ULN (normal at baseline) or \>3\*ULN and doubling baseline (\>ULN at baseline) and associated with TB \>2\*ULN; or ALT/AST\>5\*ULN; or TB\>3\*ULN. Missing 75% of planned doses during DLT OP due to treatment-related toxicities. AE not listed/DLT criteria outside DLT OP was DLT at discretion of sponsor and investigator.
Time frame: Day 1 up to Day 21 of Cycle 1
Population: DLT-evaluable analysis set included all participants who received at least 1 dose of study treatment in Phase 1b and either experienced DLT during the DLT-observation period or completed the DLT-observation period without DLT.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Percentage of Participants With DLT | 0 Percentage of participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Percentage of Participants With DLT | 1 Percentage of participants |
Primary
Phase 2 of Sub-Study A: Durable Objective Response Rate (ORR)
Durable ORR was defined as percentage of participants with confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 based on investigator assessment, lasting for at least 10 months from the date of first CR or PR until the date of the first documentation of disease progression (PD), death, or start of new anticancer therapy. CR was defined as complete disappearance of all target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 millimeter \[mm\]). PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. PD was defined as 20% increase in sum of diameters of target measurable lesions above smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm.
Time frame: From the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy
Population: Due to a business decision, no participant was enrolled in Phase 2 of sub-study A. Hence, Phase 2 was not initiated and no data was collected.
Primary
Phase 2 Sub-Study B: Objective Response Rate
ORR was defined as percentage of participants with confirmed CR or PR according to RECIST v1.1 based on investigator assessment, from the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy. CR was defined as complete disappearance of all target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 millimeter \[mm\]). PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. PD was defined as 20% increase in sum of diameters of target measurable lesions above smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm.
Time frame: From the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy (maximum of 21 months)
Population: Full analysis set included all participants who received at least 1 dose of study drug.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 Sub-Study B: Objective Response Rate | 33.3 Percentage of participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 Sub-Study B: Objective Response Rate | 0 Percentage of participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 Sub-Study B: Objective Response Rate | 14.3 Percentage of participants |
Secondary
Phase 1b of Sub-Study A: Area Under the Concentration Versus Time Curve Over the Dosing Interval (AUCtau) After Single Dose of Sasanlimab
AUCtau was defined as area under the plasma concentration time curve from time zero to the next dose.
Time frame: Cycle 1 (pre-dose on Day 1, 168 hours [Day 8] and 336 hours [Day 15] and Day 28 post-dose) (1 cycle= 28 days)
Population: Pharmacokinetic (PK) parameter analysis set was subset of safety analysis set (participants who received at least 1 dose of study drug) with participants who had at least 1 of PK parameters of interest for measured analytes related to study drug (i.e., sasanlimab). Here, 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Area Under the Concentration Versus Time Curve Over the Dosing Interval (AUCtau) After Single Dose of Sasanlimab | 12500 Micrograms*hour per milliliter | Geometric Coefficient of Variation 65 |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Area Under the Concentration Versus Time Curve Over the Dosing Interval (AUCtau) After Single Dose of Sasanlimab | 24850 Micrograms*hour per milliliter | Geometric Coefficient of Variation 17 |
Secondary
Phase 1b of Sub-Study A: Ctrough of Binimetinib
Time frame: Day 1 (pre-dose) of Cycles 1, 2, and 5 (1 cycle= 28 days)
Population: PK parameter analysis set was subset of safety analysis set (participants who received at least 1 dose of study drug) with participants who had at least 1 of PK parameters of interest for measured analytes related to study drug. Here, 'Overall Number Analyzed' signifies participants evaluable for this outcome measure. Here, 'Number Analyzed' signifies participants evaluable at specified timepoints.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Ctrough of Binimetinib | Cycle 2 Day 1 | 19.2 Nanograms per milliliter | — |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Ctrough of Binimetinib | Cycle 2 Day 1 | 40.9 Nanograms per milliliter | Geometric Coefficient of Variation 98 |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Ctrough of Binimetinib | Cycle 5 Day 1 | 35.7 Nanograms per milliliter | Geometric Coefficient of Variation 67 |
| Unknown | Phase 1b of Sub-Study A: Ctrough of Binimetinib | Cycle 1 Day 1 | — Nanograms per milliliter | — |
Secondary
Phase 1b of Sub-Study A: Ctrough of Encorafenib
Time frame: Day 1 (pre-dose) of Cycle 1, 2 and 5; Day 15 of Cycle 1 (1 cycle= 28 days)
Population: PK parameter analysis set was subset of safety analysis set (participants who received at least 1 dose of study drug) with participants who had at least 1 of PK parameters of interest for measured analytes related to study drug. Here, 'Number Analyzed' signifies participants evaluable at specified timepoints. For 'Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg)' arm, samples were not analyzed for Cycle 2 Day 1 as it was collected incorrectly due to time deviation for visits.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Ctrough of Encorafenib | Cycle 1 Day 15 | 12.2 Nanograms per milliliter | Geometric Coefficient of Variation 176 |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Ctrough of Encorafenib | Cycle 5 Day 1 | 5.0 Nanograms per milliliter | — |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Ctrough of Encorafenib | Cycle 1 Day 1 | NA Nanograms per milliliter | — |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Ctrough of Encorafenib | Cycle 5 Day 1 | 7.8 Nanograms per milliliter | Geometric Coefficient of Variation 191 |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Ctrough of Encorafenib | Cycle 1 Day 15 | 18.5 Nanograms per milliliter | Geometric Coefficient of Variation 50 |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Ctrough of Encorafenib | Cycle 1 Day 1 | NA Nanograms per milliliter | — |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Ctrough of Encorafenib | Cycle 2 Day 1 | 11.1 Nanograms per milliliter | Geometric Coefficient of Variation 204 |
Secondary
Phase 1b of Sub-Study A: Durable Objective Response Rate (ORR)
Durable ORR was defined as percentage of participants with confirmed CR or PR according to RECIST v1.1 based on investigator assessment, lasting for at least 10 months from the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy. CR was defined as complete disappearance of all target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 milli meter \[mm\]). PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. PD was defined as 20% increase in sum of diameters of target measurable lesions above smallest sum observed (over baseline if no decrease in the sum is observed during therapy) with a minimum absolute increase of 5 mm. Non-CR/Non-PD: Persistence of any non-target lesions and/or tumor marker level (if being followed) above the normal limits.
Time frame: From the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy (approximately 38.66 months)
Population: Full analysis set included all participants who received at least 1 dose of study drug.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Durable Objective Response Rate (ORR) | 25.0 Percentage of Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Durable Objective Response Rate (ORR) | 44.4 Percentage of Participants |
Secondary
Phase 1b of Sub-Study A: Maximum Observed Plasma Concentration (Cmax) of Sasanlimab
Time frame: Cycle 1 (pre-dose on Day 1, 168 hours [Day 8],336 hours [Day 15] and Day 28 post-dose) and Cycle 5 (pre-dose on Day 1 and 168 hours [Day 8] post dose) (1 cycle= 28 days)
Population: PK parameter analysis set was subset of safety analysis set (participants who received at least 1 dose of study drug) with participants who had at least 1 of PK parameters of interest for measured analytes related to study drug (i.e., sasanlimab). Here, 'Number Analyzed' signifies participants evaluable at specified timepoints.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Maximum Observed Plasma Concentration (Cmax) of Sasanlimab | Cycle 1 | 29.49 Micrograms per milliliter | Geometric Coefficient of Variation 55 |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Maximum Observed Plasma Concentration (Cmax) of Sasanlimab | Cycle 5 | 64.60 Micrograms per milliliter | — |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Maximum Observed Plasma Concentration (Cmax) of Sasanlimab | Cycle 1 | 45.04 Micrograms per milliliter | Geometric Coefficient of Variation 38 |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Maximum Observed Plasma Concentration (Cmax) of Sasanlimab | Cycle 5 | 70.90 Micrograms per milliliter | — |
Secondary
Phase 1b of Sub-Study A: Number of Participants With Adverse Events (AEs) Graded According to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs was graded by the investigator according to NCI CTCAE grade 1 to 5 version 5.0; where Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life-threatening and Grade 5=death.
Time frame: From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment (maximum exposure = 38.66 months; maximum follow-up approximately 39.66 months)
Population: Safety analysis set includes all participants who receive at least 1 dose of study drug.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Adverse Events (AEs) Graded According to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 | Grade 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Adverse Events (AEs) Graded According to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 | Grade 1 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Adverse Events (AEs) Graded According to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 | Grade 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Adverse Events (AEs) Graded According to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 | Grade 3 | 3 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Adverse Events (AEs) Graded According to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 | Grade 5 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Adverse Events (AEs) Graded According to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 | Grade 5 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Adverse Events (AEs) Graded According to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 | Grade 3 | 4 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Adverse Events (AEs) Graded According to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 | Grade 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Adverse Events (AEs) Graded According to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 | Grade 4 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Adverse Events (AEs) Graded According to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 | Grade 2 | 2 Participants |
Secondary
Phase 1b of Sub-Study A: Number of Participants With Positive Anti-Drug Antibody (ADA) and Neutralizing Antibody (NAb) Against Sasanlimab
In this outcome measure, number of ADA-positive and NAb-positive participants has been presented. A participant was considered ADA (or NAb) positive if (1) baseline titer was missing or negative and participant had \>= 1 post-treatment positive titer (treatment-induced), or (2) positive titer at baseline and had a \>= \[4-fold dilution increase\] in titer (equivalent to 0.602 unit increase in logarithm to base 10 (log10) titer from baseline in \>= 1 post-treatment sample (treatment-boosted).
Time frame: Pre-dose on Cycle 1 Day 1 until end of treatment (up to approximately 255 days) (1 cycle= 28 days)
Population: Immunogenicity analysis set was a subset of the safety analysis set (participants who received at least 1 dose of study drug) and included participants who had at least 1 analyzed sasanlimab ADA/NAb sample. All participants included in 'Overall Number of Participants Analyzed' contributed data to the table; however, may not have evaluable data for every row. Here, 'Number Analyzed' signifies participants evaluated for ADA and NAb respectively.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Positive Anti-Drug Antibody (ADA) and Neutralizing Antibody (NAb) Against Sasanlimab | ADA | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Positive Anti-Drug Antibody (ADA) and Neutralizing Antibody (NAb) Against Sasanlimab | NAb | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Positive Anti-Drug Antibody (ADA) and Neutralizing Antibody (NAb) Against Sasanlimab | ADA | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Positive Anti-Drug Antibody (ADA) and Neutralizing Antibody (NAb) Against Sasanlimab | NAb | 0 Participants |
Secondary
Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0
Chemistry parameters included: alanine aminotransferase (ALT) increase, alkaline phosphatase (ALP) increased, aspartate aminotransferase (AST) increased, blood bilirubin increased, creatinine phosphokinase (CPK) increased, chronic kidney disease (CKD), creatinine increased, hypercalcemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia, lipase increased, serum amylase increased. Chemistry abnormalities were graded as per NCI- CTCAE v 5.0 where, grade(G) 0= non-missing lab value that does not meet either of G1 through 4 criteria, G1=mild, G2=moderate, G3=severe and G4= life-threatening or disabling. Baseline is defined as the last assessment prior to the date/time of the first dose of study treatment. Number of participants with shift from baseline in hematology parameters by grades (as per CTCAE version 5.0) were reported.
Time frame: From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment (maximum exposure = 38.66 months; maximum follow-up approximately 39.66 months)
Population: Safety analysis set included all participants who received at least 1 dose of study drug.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alkaline phosphatase increased | Grade 1 to 2 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alanine aminotransferase increased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alkaline phosphatase increased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alkaline phosphatase increased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 0 to 0 | 4 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alanine aminotransferase increased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 0 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alkaline phosphatase increased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 0 to 0 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 0 to 1 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alkaline phosphatase increased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 1 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alanine aminotransferase increased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 2 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alkaline phosphatase increased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 2 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 2 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 2 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 2 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alkaline phosphatase increased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alanine aminotransferase increased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 3 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alkaline phosphatase increased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 1 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 4 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alkaline phosphatase increased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alkaline phosphatase increased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 0 to 0 | 4 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alanine aminotransferase increased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alkaline phosphatase increased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alkaline phosphatase increased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alanine aminotransferase increased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alkaline phosphatase increased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alkaline phosphatase increased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alanine aminotransferase increased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alkaline phosphatase increased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alkaline phosphatase increased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 0 to 0 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alanine aminotransferase increased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 0 to 1 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alkaline phosphatase increased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 0 to 3 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 0 to 0 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 0 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alkaline phosphatase increased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 0 to 2 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alanine aminotransferase increased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 1 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Aspartate aminotransferase increased | Grade 0 to 0 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 4 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 2 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Aspartate aminotransferase increased | Grade 0 to 1 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 1 to 1 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alanine aminotransferase increased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 3 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 4 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Aspartate aminotransferase increased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 4 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 0 to 0 | 4 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Aspartate aminotransferase increased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alanine aminotransferase increased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Aspartate aminotransferase increased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Aspartate aminotransferase increased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alanine aminotransferase increased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Aspartate aminotransferase increased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Aspartate aminotransferase increased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alanine aminotransferase increased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Aspartate aminotransferase increased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 0 to 0 | 4 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Aspartate aminotransferase increased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alanine aminotransferase increased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Aspartate aminotransferase increased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 0 to 0 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Aspartate aminotransferase increased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 0 to 1 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alanine aminotransferase increased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 0 to 2 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Aspartate aminotransferase increased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Aspartate aminotransferase increased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alanine aminotransferase increased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 0 to 0 | 4 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 0 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Aspartate aminotransferase increased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 1 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Aspartate aminotransferase increased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 1 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 1 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alanine aminotransferase increased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 1 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 2 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Aspartate aminotransferase increased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Aspartate aminotransferase increased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 3 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alanine aminotransferase increased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Aspartate aminotransferase increased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 4 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Aspartate aminotransferase increased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 0 to 0 | 4 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alanine aminotransferase increased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Aspartate aminotransferase increased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Aspartate aminotransferase increased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alanine aminotransferase increased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Aspartate aminotransferase increased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Aspartate aminotransferase increased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 0 to 0 | 3 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alanine aminotransferase increased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 0 to 1 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Aspartate aminotransferase increased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 4 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 0 to 0 | 4 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 0 to 0 | 3 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alanine aminotransferase increased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 0 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 1 to 0 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 1 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 2 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 2 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alanine aminotransferase increased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 2 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 2 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 2 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 3 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alkaline phosphatase increased | Grade 0 to 0 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 4 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 4 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 0 to 0 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 0 to 1 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 0 to 2 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alkaline phosphatase increased | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alkaline phosphatase increased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alkaline phosphatase increased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 0 to 0 | 4 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alanine aminotransferase increased | Grade 0 to 0 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 0 to 0 | 4 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alkaline phosphatase increased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alkaline phosphatase increased | Grade 1 to 0 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alanine aminotransferase increased | Grade 0 to 1 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alkaline phosphatase increased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 4 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 4 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 4 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 0 to 2 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 1 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 0 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 0 to 0 | 7 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alanine aminotransferase increased | Grade 0 to 0 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alanine aminotransferase increased | Grade 0 to 1 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alanine aminotransferase increased | Grade 0 to 2 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alanine aminotransferase increased | Grade 0 to 3 | 3 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alanine aminotransferase increased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alanine aminotransferase increased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alanine aminotransferase increased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alanine aminotransferase increased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alanine aminotransferase increased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alanine aminotransferase increased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alanine aminotransferase increased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alanine aminotransferase increased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alanine aminotransferase increased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alanine aminotransferase increased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alanine aminotransferase increased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alanine aminotransferase increased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alanine aminotransferase increased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alanine aminotransferase increased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alanine aminotransferase increased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alanine aminotransferase increased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alanine aminotransferase increased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alanine aminotransferase increased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alanine aminotransferase increased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alanine aminotransferase increased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alanine aminotransferase increased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alkaline phosphatase increased | Grade 0 to 0 | 3 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alkaline phosphatase increased | Grade 0 to 1 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alkaline phosphatase increased | Grade 0 to 2 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alkaline phosphatase increased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alkaline phosphatase increased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alkaline phosphatase increased | Grade 1 to 0 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alkaline phosphatase increased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alkaline phosphatase increased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alkaline phosphatase increased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alkaline phosphatase increased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alkaline phosphatase increased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alkaline phosphatase increased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alkaline phosphatase increased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alkaline phosphatase increased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alkaline phosphatase increased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alkaline phosphatase increased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alkaline phosphatase increased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alkaline phosphatase increased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alkaline phosphatase increased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alkaline phosphatase increased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alkaline phosphatase increased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alkaline phosphatase increased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alkaline phosphatase increased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alkaline phosphatase increased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Aspartate aminotransferase increased | Grade 0 to 0 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Aspartate aminotransferase increased | Grade 0 to 1 | 4 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Aspartate aminotransferase increased | Grade 0 to 2 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Aspartate aminotransferase increased | Grade 0 to 3 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Aspartate aminotransferase increased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Aspartate aminotransferase increased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Aspartate aminotransferase increased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Aspartate aminotransferase increased | Grade 1 to 2 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Aspartate aminotransferase increased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Aspartate aminotransferase increased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Aspartate aminotransferase increased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Aspartate aminotransferase increased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Aspartate aminotransferase increased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Aspartate aminotransferase increased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Aspartate aminotransferase increased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Aspartate aminotransferase increased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Aspartate aminotransferase increased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Aspartate aminotransferase increased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Aspartate aminotransferase increased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Aspartate aminotransferase increased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Aspartate aminotransferase increased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Aspartate aminotransferase increased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Aspartate aminotransferase increased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Aspartate aminotransferase increased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Aspartate aminotransferase increased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 0 to 0 | 8 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 0 to 3 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 0 to 0 | 4 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 0 to 1 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 0 to 2 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 0 to 3 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 0 to 4 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 0 to 0 | 3 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 0 to 1 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 0 to 2 | 3 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 1 to 1 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 2 to 2 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 0 to 0 | 6 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 0 to 1 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 0 to 2 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 0 to 0 | 4 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 0 to 1 | 5 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 0 to 0 | 8 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 0 to 1 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 0 to 0 | 8 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 0 to 1 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 0 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 1 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 2 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 2 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 2 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 2 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 2 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 3 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 4 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 0 to 0 | 8 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 0 to 1 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 0 to 0 | 3 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 0 to 1 | 3 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 0 to 2 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 0 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 1 to 1 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 1 to 2 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 1 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 2 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 3 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 4 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 4 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 0 to 0 | 7 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 0 to 1 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 0 to 0 | 7 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 0 to 1 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 1 to 0 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 0 to 0 | 7 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 0 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 0 to 3 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 1 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 1 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 1 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 1 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 2 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 3 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 4 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 0 to 0 | 8 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 0 to 1 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 0 to 0 | 5 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 0 to 1 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 0 to 3 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 1 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 1 to 3 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 2 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 2 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 2 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 2 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 2 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 3 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 4 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 0 to 0 | 5 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 0 to 1 | 3 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 0 to 2 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 0 to 3 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 1 to 1 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Alkaline phosphatase increased | Grade 3 to 0 | 1 Participants |
Secondary
Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0
Hematology parameters included: anemia, hemoglobin increased, leukocytosis, lymphocyte count decreased, lymphocyte count increased, leukocytosis, neutrophil count decreased, platelet count decreased, white blood cell decreased. Laboratory abnormalities were graded as per NCI- CTCAE v 5.0 where, grade(G) 0= non-missing lab value that does not meet either of G1 through 4 criteria, G1=mild, G2=moderate, G3=severe and G4= life-threatening or disabling. Baseline is defined as the last assessment prior to the date/time of the first dose of study treatment. Number of participants with shift from baseline in hematology parameters by grades (as per CTCAE version 5.0) were reported.
Time frame: From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment (maximum exposure = 38.66 months; maximum follow-up approximately 39.66 months)
Population: Safety analysis set included all participants who received at least 1 dose of study drug.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 1 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 1 to 2 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 4 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 2 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 0 to 0 | 4 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 0 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 3 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 0 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 1 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 1 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 4 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 1 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 1 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 4 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 1 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 1 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 4 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 2 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 4 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 2 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 4 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 3 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 0 to 0 | 4 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 3 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 4 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 0 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 4 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 4 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 0 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 4 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 0 to 0 | 4 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 0 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 2 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 1 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 4 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 1 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 1 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 1 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 1 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 2 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 2 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 2 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 2 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 0 to 0 | 4 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 3 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 2 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 4 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 3 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 4 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 3 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 4 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 4 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 3 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 0 to 0 | 3 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 4 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 4 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 4 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 4 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 4 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 0 to 0 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 0 to 1 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 0 to 0 | 4 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 0 to 2 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 0 to 0 | 3 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 0 to 1 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 0 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 0 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 0 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 2 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 2 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 4 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 4 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 0 to 0 | 7 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 0 to 0 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 0 to 1 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 0 to 2 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 0 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 1 to 1 | 4 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 1 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 2 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 3 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 4 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 4 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 4 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 4 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 4 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 0 to 0 | 8 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 0 to 1 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 1 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 3 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 4 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 4 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 4 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 4 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 4 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 0 to 0 | 9 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 0 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 0 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 0 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 1 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 1 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 1 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 1 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 1 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 2 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 2 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 2 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 2 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 3 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 3 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 3 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 4 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 4 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 4 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 4 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 0 to 0 | 3 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 0 to 1 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 0 to 2 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 0 to 4 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 1 to 2 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 2 to 2 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 0 to 0 | 9 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 0 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 0 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 1 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 1 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 1 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 1 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 1 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 2 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 2 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 3 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 3 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 4 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 4 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 4 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 4 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 0 to 1 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 0 to 2 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 0 to 0 | 7 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 0 to 1 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 1 to 2 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 0 to 0 | 8 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 1 to 3 | 00 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 2 to 2 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 4 to 3 | 0 Participants |
Secondary
Phase 1b of Sub-Study A: Objective Response Rate
Objective response rate is defined as percentage of participants with confirmed best overall response of CR or PR according to RECIST v1.1 from the date of first dose of study treatment until the date of the first documentation of PD. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. PD was defined as 20% increase in sum of diameters of target measurable lesions above smallest sum observed (over baseline if no decrease in the sum is observed during therapy) with a minimum absolute increase of 5 mm. Non-CR/Non-PD: Persistence of any non-target lesions and/or tumor marker level (if being followed) above the normal limits.
Time frame: From the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy (approximately 38.66 months)
Population: Full analysis set included all participants who received at least 1 dose of study drug.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Objective Response Rate | 50.0 Percentage of Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Objective Response Rate | 44.4 Percentage of Participants |
Secondary
Phase 1b of Sub-Study A: Pre-dose Concentration During Multiple Dosing (Ctrough) of Sasanlimab
Time frame: Cycle 5 Day 1 (pre-dose) (1 cycle= 28 days)
Population: PK parameter analysis set was subset of safety analysis set (participants who received at least 1 dose of study drug) with participants who had at least 1 of PK parameters of interest for measured analytes related to study drug (i.e., sasanlimab). Here, 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Pre-dose Concentration During Multiple Dosing (Ctrough) of Sasanlimab | 37.97 Microgram per milliliter | Geometric Coefficient of Variation 20 |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Pre-dose Concentration During Multiple Dosing (Ctrough) of Sasanlimab | 40.24 Microgram per milliliter | — |
Secondary
Phase 1b of Sub-Study A: Time for Cmax (Tmax) of Sasanlimab
Time frame: Cycle 1 (pre-dose on Day 1, 168 hours [Day 8], 336 hours [Day 15] and Day 28 post-dose) and Cycle 5 (pre-dose on Day 1 and 168 hours [Day 8] post dose) (1 cycle= 28 days)
Population: PK parameter analysis set was subset of safety analysis set (participants who received at least 1 dose of study drug) with participants who had at least 1 of PK parameters of interest for measured analytes related to study drug (i.e., sasanlimab). Here, 'Number Analyzed' signifies participants evaluable at specified timepoints.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Time for Cmax (Tmax) of Sasanlimab | Cycle 1 | 164 Hour |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Time for Cmax (Tmax) of Sasanlimab | Cycle 5 | 168 Hour |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Time for Cmax (Tmax) of Sasanlimab | Cycle 1 | 209 Hour |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study A: Time for Cmax (Tmax) of Sasanlimab | Cycle 5 | 162 Hour |
Secondary
Phase 1b of Sub-Study B: Cmax of Axitinib
Time frame: Cycle 1: pre-dose on Day 1, Day 8 and 3 hours post-dose on Day 1; Cycle 5: pre-dose on Day 1, Day 8 and 3 hours post-dose on Day 1 (1 cycle= 21 days)
Population: PK parameter analysis set was subset of safety analysis set (participants who received at least 1 dose of study drug) with participants who had at least 1 of PK parameters of interest for measured analytes related to study drug. Here, ''Number of Participants Analyzed signifies participants evaluable for this outcome measure and contributed date to the table. Here, 'Number Analyzed' signifies participants evaluable at specified timepoints.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Cmax of Axitinib | Cycle 5 Day 8 | 13.10 Nanograms per milliliter | — |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Cmax of Axitinib | Cycle 1 Day 1 | 5.094 Nanograms per milliliter | — |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Cmax of Axitinib | Cycle 1 Day 8 | 3.440 Nanograms per milliliter | — |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Cmax of Axitinib | Cycle 5 Day 8 | 24.85 Nanograms per milliliter | — |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Cmax of Axitinib | Cycle 5 Day 1 | 33.79 Nanograms per milliliter | Geometric Coefficient of Variation 73 |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Cmax of Axitinib | Cycle 1 Day 1 | 22.81 Nanograms per milliliter | Geometric Coefficient of Variation 80 |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Cmax of Axitinib | Cycle 1 Day 8 | 13.74 Nanograms per milliliter | Geometric Coefficient of Variation 106 |
Secondary
Phase 1b of Sub-Study B: Cmax of Sasanlimab
Time frame: Cycle 1: pre-dose, 168 hours post-dose on Day 1, Cycle 5: pre-dose, 168 hours post-dose on Day 1 (1 cycle= 21 days)
Population: PK parameter analysis set was subset of safety analysis set (participants who received at least 1 dose of study drug) with participants who had at least 1 of PK parameters of interest for measured analytes related to study drug (i.e., sasanlimab). Here, ''Number of Participants Analyzed'' signifies participants evaluable for this outcome measure. Here, 'Number Analyzed' signifies participants evaluable at specified timepoints.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Cmax of Sasanlimab | Cycle 5 | 23080 Nanograms per milliliter | — |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Cmax of Sasanlimab | Cycle 1 | 8840 Nanograms per milliliter | Geometric Coefficient of Variation 127 |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Cmax of Sasanlimab | Cycle 1 | 11570 Nanograms per milliliter | Geometric Coefficient of Variation 79 |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Cmax of Sasanlimab | Cycle 5 | 47340 Nanograms per milliliter | Geometric Coefficient of Variation 42 |
Secondary
Phase 1b of Sub-Study B: Cmax of SEA-TGT
Time frame: Cycle 1: pre-dose, 168 hours post-dose on Day 1, Cycle 5: pre-dose, 168 hours post-dose on Day 1 (1 cycle= 21 days)
Population: PK parameter analysis set: subset of safety analysis set (participants who received at least 1 dose of study drug) with participants who had at least 1 of PK parameters of interest for measured analytes related to study drug. ''Number of Participants Analyzed'': participants evaluable for this outcome measure. 'Number Analyzed': participants evaluable at specified timepoints. Data for only those participants who received SEA-TGT were planned to be reported for this outcome measure.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Cmax of SEA-TGT | Cycle 1 | 42550 Nanograms per milliliter | Geometric Coefficient of Variation 109 |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Cmax of SEA-TGT | Cycle 5 | 32660 Nanograms per milliliter | Geometric Coefficient of Variation 17 |
Secondary
Phase 1b of Sub-Study B: Duration of Response (DR)
DR was defined for participants with confirmed objective response (OR) as time from date of first documentation of OR to the date of first documentation of PD or death (any cause), whichever occurred first. OR=CR or PR according to RECIST v1.1 based on investigator assessment. CR and PR must be confirmed by repeat assessments performed no \<4 weeks after criteria for response were first met. CR=complete disappearance of all target lesions (TLs) with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). PR=greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions (TMLs). PD=20% increase in sum of diameters of TMLs above smallest sum observed (over baseline if no decrease in sum was observed during therapy), with a minimum absolute increase of 5 mm.
Time frame: From the date of first documentation of OR to the date of first documentation of PD or death, whichever occurred first (maximum of 21 months)
Population: Data was not estimable due to insufficient number of participants (with events) evaluable for this outcome measure.
Secondary
Phase 1b of Sub-Study B: Number of Participants With Adverse Events Graded According to NCI-CTCAE Version 5.0
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs were graded by the investigator according to NCI CTCAE version 5.0; where Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life-threatening and Grade 5=death.
Time frame: From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment (maximum exposure = 38.66 months; maximum follow-up approximately 39.66 months)
Population: Safety analysis set included all participants who received at least 1 dose of study drug.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Adverse Events Graded According to NCI-CTCAE Version 5.0 | Grade 3 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Adverse Events Graded According to NCI-CTCAE Version 5.0 | Grade 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Adverse Events Graded According to NCI-CTCAE Version 5.0 | Grade 5 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Adverse Events Graded According to NCI-CTCAE Version 5.0 | Grade 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Adverse Events Graded According to NCI-CTCAE Version 5.0 | Grade 2 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Adverse Events Graded According to NCI-CTCAE Version 5.0 | Grade 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Adverse Events Graded According to NCI-CTCAE Version 5.0 | Grade 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Adverse Events Graded According to NCI-CTCAE Version 5.0 | Grade 4 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Adverse Events Graded According to NCI-CTCAE Version 5.0 | Grade 3 | 4 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Adverse Events Graded According to NCI-CTCAE Version 5.0 | Grade 5 | 1 Participants |
Secondary
Phase 1b of Sub-Study B: Number of Participants With Positive Anti-Drug Antibody (ADA) Against Sasanlimab and SEA-TGT
A participant was considered ADA (or NAb) positive if (1) baseline titer was missing or negative and participant had \>= 1 post-treatment positive titer (treatment-induced), or (2) positive titer at baseline and had a \>= \[4-fold dilution increase\] in titer (equivalent to 0.602 unit increase in logarithm to base 10 (log10) titer from baseline in \>= 1 post-treatment sample (treatment-boosted).
Time frame: Pre-dose on Cycle 1 Day 1 until end of treatment (up to approximately 21 months) (1 cycle= 21 days)
Population: Immunogenicity analysis set included participants who had at least 1 analyzed sasanlimab ADA/NAb sample. Here ''Number analyzed'' signifies number of participants with at least one post-treatment ADA result for respective category.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Positive Anti-Drug Antibody (ADA) Against Sasanlimab and SEA-TGT | ADA against sasanlimab | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Positive Anti-Drug Antibody (ADA) Against Sasanlimab and SEA-TGT | ADA against sasanlimab | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Positive Anti-Drug Antibody (ADA) Against Sasanlimab and SEA-TGT | ADA against SEA-TGT | 0 Participants |
Secondary
Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0
Chemistry parameters included: alanine aminotransferase (ALT) increased, alkaline phosphatase (ALP) increased, aspartate aminotransferase (AST) increased, blood bilirubin increased, creatinine phosphokinase (CPK) increased, chronic kidney disease (CKD), creatinine increased, hypercalcemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia, lipase increased, serum amylase increased. Chemistry abnormalities were graded as per NCI- CTCAE v 5.0 where, grade(G) 0= non-missing lab value that does not meet either of G1 through 4 criteria, G1=mild, G2=moderate, G3=severe and G4= life-threatening or disabling. Baseline is defined as the last assessment prior to the date/time of the first dose of study treatment. Number of participants with shift from baseline in hematology parameters by grades (as per CTCAE version 5.0) were reported.
Time frame: From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment (maximum exposure = 38.66 months; maximum follow-up approximately 39.66 months)
Population: Safety analysis set included all participants who received at least 1 dose of study drug.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 0 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | AST increased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | AST increased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 0 to 2 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | AST increased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | AST increased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | AST increased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | AST increased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | AST increased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | AST increased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 0 to 0 | 3 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 1 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 1 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 1 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 3 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 1 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 1 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 4 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 2 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 4 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALT increased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 4 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 3 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 4 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 4 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 4 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 0 to 0 | 3 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 4 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 0 to 0 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 0 to 1 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 0 to 0 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 0 to 1 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 1 to 2 | 00 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 2 to 1 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 2 to 2 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 0 to 0 | 3 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 0 to 0 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 0 to 0 | 3 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 1 to 1 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 0 to 0 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 0 to 1 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 0 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 0 to 0 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 0 to 1 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 1 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 2 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 2 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 2 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 0 to 0 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 2 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | AST increased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | AST increased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 2 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALT increased | Grade 0 to 0 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALT increased | Grade 0 to 1 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALT increased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALT increased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 3 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALT increased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 0 to 1 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALT increased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALT increased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALT increased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALT increased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALT increased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALT increased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 0 to 0 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALT increased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALT increased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALT increased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 4 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALT increased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 0 to 1 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALT increased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALT increased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALT increased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALT increased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 0 to 0 | 3 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALT increased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALT increased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALT increased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALT increased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALP increased | Grade 0 to 0 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALP increased | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALP increased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALP increased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALP increased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 0 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALP increased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALP increased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALP increased | Grade 1 to 2 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALP increased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALP increased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALP increased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALP increased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALP increased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALP increased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALP increased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALP increased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALP increased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALP increased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALP increased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALP increased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALP increased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALP increased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALP increased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALP increased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALP increased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | AST increased | Grade 0 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | AST increased | Grade 0 to 1 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | AST increased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | AST increased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | AST increased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | AST increased | Grade 1 to 0 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | AST increased | Grade 1 to 1 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | AST increased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | AST increased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | AST increased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | AST increased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | AST increased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | AST increased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 1 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | AST increased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 0 to 0 | 3 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 0 to 0 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 0 to 1 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | AST increased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 0 to 0 | 3 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 0 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 1 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 2 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 2 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 2 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 2 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 2 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 2 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 0 to 0 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 3 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALT increased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALP increased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | AST increased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 0 to 0 | 5 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 0 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 4 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 0 to 0 | 6 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypernatremia | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 0 to 0 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 0 to 1 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 0 to 2 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 1 to 2 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 1 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 2 to 2 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 2 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 3 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 4 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 4 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 4 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 4 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 4 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 0 to 0 | 6 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypocalcemia | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 0 to 0 | 5 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 0 to 1 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | AST increased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypoglycemia | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 0 to 0 | 4 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 0 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 0 to 2 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 1 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 1 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 1 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 1 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 1 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 2 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 3 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 4 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypokalemia | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 0 to 0 | 5 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 0 to 1 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 0 to 0 | 4 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 0 to 1 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 0 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 1 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 2 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 2 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 2 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 2 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 2 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 3 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 4 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyponatremia | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 0 to 0 | 4 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 0 to 1 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Lipase increased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 0 to 0 | 4 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 0 to 1 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 1 to 2 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Serum amylase increased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | AST increased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | AST increased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | AST increased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | AST increased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | AST increased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | AST increased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | AST increased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 0 to 0 | 6 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 1 to 0 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | CPK increased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 0 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 0 to 1 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 0 to 2 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 1 to 2 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 2 to 2 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 0 to 0 | 3 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 1 to 1 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 1 to 2 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Creatinine increased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 0 to 0 | 5 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 0 to 1 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | AST increased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | AST increased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALT increased | Grade 0 to 0 | 5 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALT increased | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALT increased | Grade 0 to 2 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALT increased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALT increased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALT increased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALT increased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALT increased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALT increased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALT increased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALT increased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALT increased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALT increased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALT increased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALT increased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALT increased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALT increased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALT increased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALT increased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALT increased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALT increased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALT increased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALT increased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALT increased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALT increased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALP increased | Grade 0 to 0 | 4 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALP increased | Grade 0 to 1 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALP increased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALP increased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALP increased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALP increased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALP increased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALP increased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALP increased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALP increased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALP increased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALP increased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALP increased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALP increased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALP increased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALP increased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALP increased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALP increased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALP increased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALP increased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALP increased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALP increased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALP increased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | ALP increased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | AST increased | Grade 0 to 0 | 5 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | AST increased | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | AST increased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | AST increased | Grade 0 to 3 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | AST increased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | AST increased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | AST increased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | AST increased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | AST increased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | AST increased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | AST increased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | AST increased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | AST increased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | AST increased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypercalcemia | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 0 to 0 | 5 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 0 to 1 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hyperkalemia | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 0 to 0 | 6 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 0 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 1 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 2 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 2 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 2 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 2 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 2 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameters Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 3 to 2 | NA Participants |
Secondary
Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0
Hematology parameters included: anemia, hemoglobin increased, leukocytosis, lymphocyte count decreased, lymphocyte count increased, neutrophil count decreased, platelet count decreased, white blood cell decreased. Laboratory abnormalities were graded as per NCI- CTCAE v 5.0 where, grade(G) 0= non-missing lab value that does not meet either of G1 through 4 criteria, G1=mild, G2=moderate, G3=severe and G4= life-threatening or disabling. Baseline is defined as the last assessment prior to the date/time of the first dose of study treatment. Number of participants with shift from baseline in hematology parameters by grades (as per CTCAE version 5.0) were reported.
Time frame: From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment (maximum exposure = 39.3 months; maximum follow-up approximately 39.66 months)
Population: Safety analysis set included all participants who received at least 1 dose of study drug.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 4 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 2 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 4 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 0 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 4 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 2 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 4 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 0 to 0 | 3 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 2 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 3 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 3 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 4 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 4 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 3 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 4 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 4 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 4 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 4 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 0 to 0 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 1 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 0 to 0 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 0 to 1 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 1 to 2 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 2 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 0 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 0 to 1 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 0 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 1 to 1 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 1 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 0 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 3 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 3 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 4 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 4 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 4 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 4 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 4 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 4 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 1 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 4 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 0 to 0 | 3 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 4 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 0 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 2 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 4 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 0 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 0 to 0 | 3 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 1 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 0 to 0 | 3 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 2 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 1 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 0 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 1 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 0 to 0 | 3 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 1 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 0 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 1 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 2 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 1 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 2 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 3 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 1 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 4 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 2 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 1 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 3 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 1 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 1 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 4 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 4 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 0 to 0 | 6 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 0 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 2 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 0 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 0 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 1 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 2 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 2 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 3 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 4 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 0 to 0 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 2 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 1 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 3 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 4 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 4 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 4 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 4 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 4 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 0 to 0 | 6 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 0 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 1 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 1 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 1 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 1 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 2 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 2 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 2 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 3 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 3 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 4 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 4 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 4 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Leukocytosis | Grade 4 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 0 to 2 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 0 to 3 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 0 to 4 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 1 to 4 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 2 to 2 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 3 to 0 | 00 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 0 to 0 | 6 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 0 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 0 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 1 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 1 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 1 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 1 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 1 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 2 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 3 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 3 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 4 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 4 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 4 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 4 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 4 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 0 to 0 | 6 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Neutrophil count decreased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 0 to 0 | 5 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 0 to 1 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 0 to 0 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 0 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 1 to 1 | 3 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 2 to 2 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 2 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 3 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 4 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 4 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 4 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Platelet count decreased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 0 to 0 | 5 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 0 to 1 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | White blood cell decreased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameters Values Based on CTCAE V5.0 | Anemia | Grade 0 to 1 | 0 Participants |
Secondary
Phase 1b of Sub-Study B: Objective Response Rate
ORR was defined as percentage of participants with confirmed CR or PR according to RECIST v1.1 based on investigator assessment, from the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy. CR was defined as complete disappearance of all target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. PD was defined as 20% increase in sum of diameters of target measurable lesions above smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm. Two sided 95% CI was based on Clopper-Pearson method.
Time frame: From the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy, whichever occurred first (maximum of 21 months)
Population: Full analysis set included all participants who received at least 1 dose of study drug.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Objective Response Rate | 0.0 Percentage of participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Objective Response Rate | 0.0 Percentage of participants |
Secondary
Phase 1b of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of Axitinib
Time frame: Pre-dose on Cycle 1 Day 1 and Day 8; pre-dose on Cycle 5 Day 1 and Day 8 (1 cycle= 21 days)
Population: PK parameter analysis set was subset of safety analysis set (participants who received at least 1 dose of study drug) with participants who had at least 1 of PK parameters of interest for measured analytes related to study drug. Here, Overall Number of Participants Analyzed signifies participants evaluable for this outcome measure. Here, 'Number Analyzed' signifies participants evaluable at specified timepoints.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of Axitinib | Cycle 1 Day 8 | 3.440 Nanograms per milliliter | — |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of Axitinib | Cycle 5 Day 8 | 13.10 Nanograms per milliliter | — |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of Axitinib | Cycle 1 Day 8 | 13.74 Nanograms per milliliter | Geometric Coefficient of Variation 106 |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of Axitinib | Cycle 5 Day 1 | 29.42 Nanograms per milliliter | — |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of Axitinib | Cycle 5 Day 8 | 24.85 Nanograms per milliliter | — |
| Unknown | Phase 1b of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of Axitinib | Cycle 1 Day 1 | — Nanograms per milliliter | — |
Secondary
Phase 1b of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of Sasanlimab
Time frame: Pre-dose on Cycle 1 Day 1 and Cycle 5 Day 1 (1 cycle= 21 days)
Population: PK parameter analysis set was subset of safety analysis set (participants who received at least 1 dose of study drug) with participants who had at least 1 of PK parameters of interest for measured analytes related to study drug. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure and 'Number Analyzed' signifies participants evaluable at specified timepoints.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of Sasanlimab | Cycle 5 | 23000 Nanograms per milliliter | — |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of Sasanlimab | Cycle 5 | 23170 Nanograms per milliliter | Geometric Coefficient of Variation 29 |
| Unknown | Phase 1b of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of Sasanlimab | Cycle 1 | — Nanograms per milliliter | — |
Secondary
Phase 1b of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of SEA-TGT
Time frame: Pre-dose on Cycle 1 Day 1; pre-dose on Cycle 5 Day 1 (1 cycle= 21 days)
Population: PK parameter analysis set: subset of safety analysis set (participants who received at least 1 dose of study drug) with participants who had at least 1 of PK parameters measured. 'Number of Participants Analyzed': participants evaluable for this outcome measure, 'Number Analyzed': participants evaluable at specified timepoints. Data for only those participants who received SEA-TGT were planned to be reported hence Phase 1b of SSB: Sasanlimab (225 mg) + Axitinib (5 mg) arm was not reported.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of SEA-TGT | Cycle 5 | 4813 Nanograms per milliliter | Geometric Coefficient of Variation 35 |
| Unknown | Phase 1b of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of SEA-TGT | Cycle 1 | — Nanograms per milliliter | — |
Secondary
Phase 1b of Sub-Study B: Progression-Free Survival (PFS)
PFS is defined as the time from the date of first dose of study treatment to the date of first documentation of PD or death due to any cause, whichever occurred first. PD=20% increase in sum of diameters of target measurable lesions above smallest sum observed (over baseline if no decrease in sum was observed during therapy), with a minimum absolute increase of 5 mm.
Time frame: From the date of first dose of study treatment to the date of first documentation of PD or death due to any cause, whichever occurred first (maximum of 21 months)
Population: Full analysis set included all participants who received at least 1 dose of study drug.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Progression-Free Survival (PFS) | 3.6 Months |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 1b of Sub-Study B: Progression-Free Survival (PFS) | 6.5 Months |
Secondary
Phase 1b of Sub-Study B: Time to Tumor Response (TTR)
TTR is defined for participants with confirmed objective response as the time from the date of first dose of study treatment to the date of first documentation of objective response (CR or PR) which was subsequently confirmed. CR=complete disappearance of all target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). PR=greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions.
Time frame: From the date of first dose of study treatment to the date of first documentation of objective response (CR or PR) (maximum of 21 months)
Population: Data was not estimable due to insufficient number of participants (with events) evaluable for this outcome measure.
Secondary
Phase 2 of Sub-Study A: Area Under the Concentration Versus Time Curve Over the Dosing Interval (AUCtau) After Single Dose of Sasanlimab
Time frame: Cycle 1 (pre-dose on Day 1, 336 hours [Day 15] and Day 28 post-dose) (1 cycle= 28 days)
Population: Due to a business decision, no participant was enrolled in Phase 2 of sub-study A. Hence, Phase 2 was not initiated and no data was collected.
Secondary
Phase 2 of Sub-Study A: Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (EORTC QLQ-C30) Score
EORTC QLQ-C30: consisted of 30 questions grouped into 5 functional scales (physical, role, cognitive, emotional, and social); a global health status/global quality of life scale; 3 symptom scales (fatigue, pain, nausea and vomiting); and 6 single items that assessed additional symptoms (dyspnea, appetite loss, sleep disturbance, constipation, and diarrhea), and financial impact. All scales and single item measures ranged in score from 0 to 100. Higher scores on the global health status/quality of life scale represent higher health status/quality of life. Higher scores on the functional scales represent higher levels of functioning. Higher scores on the symptom scales and single items represent a greater presence of symptoms or financial impact.
Time frame: Baseline up to end of treatment
Population: Due to a business decision, no participant was enrolled in Phase 2 of sub-study A. Hence, Phase 2 was not initiated and there was no data collection for it.
Secondary
Phase 2 of Sub-Study A: Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC), Quality of Life Questionnaire-Lung Cancer 13 (QLQ- LC13) Score
The EORTC QLQ-LC13 is the lung cancer specific module of the EORTC Quality of Life Questionnaire. The EORTC QLQ-LC13 consisted of 13 questions which included 1 multi-item scale and 9 single items assessing symptoms (dyspnea, cough, hemoptysis, and site specific pain), side effects (sore mouth, dysphagia, peripheral neuropathy, and alopecia), and pain medication use. The item scale ranged from 1 to 4 (1 = Not at all; 4 = Very Much) where the EORTC-QLQ-LC13 scoring algorithm was applied to convert to a 0 to 100 point scale where 100 is best quality of life (QOL), for comparability. Higher scores are reflective of a greater presence of symptoms.
Time frame: Baseline up to end of treatment
Population: Due to a business decision, no participant was enrolled in Phase 2 of sub-study A. Hence, Phase 2 was not initiated and there was no data collection for it.
Secondary
Phase 2 of Sub-Study A: Ctrough of Binimetinib
Time frame: Cycle 5 Day 1 (pre-dose)
Population: Due to a business decision, no participant was enrolled in Phase 2 of sub-study A. Hence, Phase 2 was not initiated and no data was collected.
Secondary
Phase 2 of Sub-Study A: Ctrough of Encorafenib
Time frame: Cycle 5 Day 1 (pre-dose)
Population: Due to a business decision, no participant was enrolled in Phase 2 of sub-study A. Hence, Phase 2 was not initiated and no data was collected.
Secondary
Phase 2 of Sub-Study A: Duration of Response (DR)
DR was defined for participants with confirmed OR as time from date of first documentation of OR to the date of first documentation of PD or death (any cause), whichever occurred first. OR=CR or PR according to RECIST v1.1 based on investigator assessment. CR and PR must be confirmed by repeat assessments performed no \<4 weeks after criteria for response were first met. CR=complete disappearance of all target lesions (TLs) with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). PR=greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions (TMLs). PD=20% increase in sum of diameters of TMLs above smallest sum observed (over baseline if no decrease in sum was observed during therapy), with a minimum absolute increase of 5 mm.
Time frame: From the date of first documentation of OR to the date of the first documentation of PD or death due to any cause, whichever occurred first
Population: Due to a business decision, no participant was enrolled in Phase 2 of sub-study A. Hence, Phase 2 was not initiated and no data was collected.
Secondary
Phase 2 of Sub-Study A: Maximum Observed Plasma Concentration (Cmax) of Sasanlimab
Time frame: Cycle 1 (pre-dose on Day 1, 336 hours [Day 15] and Day 28 post-dose) and Cycle 5 Day 1 (pre-dose) (1 cycle= 28 days)
Population: Due to a business decision, no participant was enrolled in Phase 2 of sub-study A. Hence, Phase 2 was not initiated and no data was collected.
Secondary
Phase 2 of Sub-Study A: Number of Participants With Adverse Events Graded According to NCI-CTCAE Version 5.0
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs were planned to be graded by the investigator according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version (v) 5.0; where Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life-threatening and Grade 5=death.
Time frame: From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment
Population: Due to a business decision, no participant was enrolled in Phase 2 of sub-study A. Hence, Phase 2 was not initiated and no data was collected.
Secondary
Phase 2 of Sub-Study A: Number of Participants With Laboratory Abnormalities
Hematology and clinical chemistry parameters were planned to be assessed.
Time frame: From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment
Population: Due to a business decision, no participant was enrolled in Phase 2 of sub-study A. Hence, Phase 2 was not initiated and no data was collected.
Secondary
Phase 2 of Sub-Study A: Number of Participants With Positive Anti-Drug Antibody (ADA) and Neutralizing Antibody (NAb) Against Sasanlimab
Time frame: Pre-dose on Cycle 1 Day 1 until end of treatment
Population: Due to a business decision, no participant was enrolled in Phase 2 of sub-study A. Hence, Phase 2 was not initiated and no data was collected.
Secondary
Phase 2 of Sub-Study A: Objective Response (OR) Rate by Programmed Death Ligand-1 (PD-L1) Expression at Baseline
OR rate is defined as percentage of participants with CR or PR according to RECIST v1.1 based on investigator assessment. CR=complete disappearance of all target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). PR=greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. OR by PD-L1 expression at baseline was planned to be assessed.
Time frame: From the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy
Population: Due to a business decision, no participant was enrolled in Phase 2 of sub-study A. Hence, Phase 2 was not initiated and no data was collected.
Secondary
Phase 2 of Sub-Study A: Objective Response Rate
Objective response (OR) rate is defined as percentage of participants with confirmed best overall response of CR or PR according to RECIST v1.1 from the date of first dose of study treatment until the date of the first documentation of PD. CR was defined as complete disappearance of all target lesions with the exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions.
Time frame: From the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy
Population: Due to a business decision, no participant was enrolled in Phase 2 of sub-study A. Hence, Phase 2 was not initiated and no data was collected.
Secondary
Phase 2 of Sub-Study A: Overall Survival (OS)
OS is defined as the time from the date of first dose of study treatment to the date of death due to any cause. Participants last known to be alive were planned to be censored at the date of last contact.
Time frame: From the date of first dose of study treatment to the date of death due to any cause or censoring date
Population: Due to a business decision, no participant was enrolled in Phase 2 of sub-study A. Hence, Phase 2 was not initiated and no data was collected.
Secondary
Phase 2 of Sub-Study A: Pre-dose Concentration During Multiple Dosing (Ctrough) of Sasanlimab
Time frame: Cycle 5 Day 1 (pre-dose) (1 cycle= 28 days)
Population: Due to a business decision, no participant was enrolled in Phase 2 of sub-study A. Hence, Phase 2 was not initiated and no data was collected.
Secondary
Phase 2 of Sub-Study A: Progression-Free Survival (PFS)
PFS is defined as the time from the date of first dose of study treatment to the date of first documentation of PD or death due to any cause, whichever occurred first. PD=20% increase in sum of diameters of target measurable lesions above smallest sum observed (over baseline if no decrease in sum was observed during therapy), with a minimum absolute increase of 5 mm.
Time frame: From the date of first dose of study treatment to the date of first documentation of PD or death due to any cause, whichever occurred first
Population: Due to a business decision, no participant was enrolled in Phase 2 of sub-study A. Hence, Phase 2 was not initiated and no data was collected.
Secondary
Phase 2 of Sub-Study A: Time for Cmax (Tmax) of Sasanlimab
Time frame: Cycle 1 (pre-dose on Day 1, 336 hours [Day 15] and Day 28 post-dose) and Cycle 5 Day 1 (pre-dose) (1 cycle= 28 days)
Population: Due to a business decision, no participant was enrolled in Phase 2 of sub-study A. Hence, Phase 2 was not initiated and no data was collected.
Secondary
Phase 2 of Sub-Study A: Time to Tumor Response (TTR)
TTR is defined for participants with confirmed objective response as the time from the date of first dose of study treatment to the date of first documentation of objective response (CR or PR) which was subsequently confirmed. CR=complete disappearance of all target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). PR=greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions.
Time frame: From the date of first dose of study treatment to the date of first documentation of objective response
Population: Due to a business decision, no participant was enrolled in Phase 2 of sub-study A. Hence, Phase 2 was not initiated and no data was collected.
Secondary
Phase 2 of Sub-Study B: Cmax of Axitinib
Time frame: Cycle 1: pre-dose on Day 1, Day 8 and 3 hours post-dose on Day 1; Cycle 5: pre-dose on Day 1, Day 8 and 3 hours post-dose on Day 1 (1 cycle= 21 days)
Population: PK parameter analysis set was subset of safety analysis set (participants who received at least 1 dose of study drug) with participants who had at least 1 of PK parameters of interest for measured analytes related to study drug. Here, Overall Number of Participants Analyzed signifies participants evaluable for this outcome measure. Here, 'Number Analyzed' signifies participants evaluable at specified timepoints.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Cmax of Axitinib | Cycle 1 Day 1 | 37.43 Nanograms per milliliter | Geometric Coefficient of Variation 85 |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Cmax of Axitinib | Cycle 1 Day 8 | 39.50 Nanograms per milliliter | — |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Cmax of Axitinib | Cycle 1 Day 8 | 2.360 Nanograms per milliliter | — |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Cmax of Axitinib | Cycle 1 Day 1 | 18.23 Nanograms per milliliter | — |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Cmax of Axitinib | Cycle 5 Day 1 | 11.10 Nanograms per milliliter | — |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Cmax of Axitinib | Cycle 1 Day 8 | 2.708 Nanograms per milliliter | Geometric Coefficient of Variation 132 |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Cmax of Axitinib | Cycle 5 Day 1 | 7.710 Nanograms per milliliter | — |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Cmax of Axitinib | Cycle 1 Day 1 | 11.18 Nanograms per milliliter | Geometric Coefficient of Variation 112 |
Secondary
Phase 2 of Sub-Study B: Cmax of Sasanlimab
Time frame: Cycle 1: pre-dose, 168 hours post-dose on Day 1, Cycle 5: pre-dose, 168 hours post-dose on Day 1 (1 cycle= 21 days)
Population: PK parameter analysis set was subset of safety analysis set (participants who received at least 1 dose of study drug) with participants who had at least 1 of PK parameters of interest for measured analytes related to study drug. 'Number Analyzed' signifies participants evaluable at specified timepoints.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Cmax of Sasanlimab | Cycle 1 | 11780 Nanograms per milliliter | Geometric Coefficient of Variation 45 |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Cmax of Sasanlimab | Cycle 1 | 13810 Nanograms per milliliter | — |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Cmax of Sasanlimab | Cycle 5 | 43500 Nanograms per milliliter | — |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Cmax of Sasanlimab | Cycle 1 | 10350 Nanograms per milliliter | Geometric Coefficient of Variation 45 |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Cmax of Sasanlimab | Cycle 5 | 20600 Nanograms per milliliter | — |
Secondary
Phase 2 of Sub-Study B: Cmax of SEA-TGT
Time frame: Cycle 1: pre-dose, 168 hours post-dose on Day 1, Cycle 5: pre-dose, 168 hours post-dose on Day 1 (1 cycle= 21 days)
Population: PK parameter analysis set was subset of safety analysis set (participants who received at least 1 dose of study drug) with participants who had at least 1 of PK parameters of interest for measured analytes related to study drug. Here, 'Number Analyzed' signifies participants evaluable at specified timepoints.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Cmax of SEA-TGT | Cycle 1 | 36970 Nanograms per milliliter | Geometric Coefficient of Variation 36 |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Cmax of SEA-TGT | Cycle 1 | 35500 Nanograms per milliliter | — |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Cmax of SEA-TGT | Cycle 5 | 43000 Nanograms per milliliter | — |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Cmax of SEA-TGT | Cycle 1 | 30590 Nanograms per milliliter | Geometric Coefficient of Variation 39 |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Cmax of SEA-TGT | Cycle 5 | 44900 Nanograms per milliliter | — |
Secondary
Phase 2 of Sub-Study B: Duration of Response (DR)
DR was defined for participants with confirmed OR as time from date of first documentation of OR to the date of first documentation of PD or death (any cause), whichever occurred first. OR=CR or PR according to RECIST v1.1 based on investigator assessment. CR and PR must be confirmed by repeat assessments performed no \<4 weeks after criteria for response were first met. CR=complete disappearance of all target lesions (TLs) with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). PR=greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions (TMLs). PD=20% increase in sum of diameters of TMLs above smallest sum observed (over baseline if no decrease in sum was observed during therapy), with a minimum absolute increase of 5 mm.
Time frame: From date of first documentation of OR to the date of first documentation of PD or death, whichever occurred first (maximum of 21 months)
Population: Full analysis set included all participants who received at least 1 dose of study drug. Here, Overall Number of Participants Analyzed signifies participants evaluable for this outcome measure and included only those participants with confirmed OR.'
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Duration of Response (DR) | NA Months |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Duration of Response (DR) | NA Months |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Duration of Response (DR) | 5.8 Months |
Secondary
Phase 2 of Sub-Study B: Number of Participants With Adverse Events Graded According to NCI-CTCAE Version 5.0
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs were graded by the investigator according to NCI CTCAE version 5.0; where Grade 1=mild, Grade 2=moderate, Grade 3=severe, Grade 4=life-threatening and Grade 5=death
Time frame: From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment (maximum exposure = 38.66 months; maximum follow-up approximately 39.66 months)
Population: Safety analysis set included all participants who received at least 1 dose of study drug.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Adverse Events Graded According to NCI-CTCAE Version 5.0 | Grade 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Adverse Events Graded According to NCI-CTCAE Version 5.0 | Grade 4 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Adverse Events Graded According to NCI-CTCAE Version 5.0 | Grade 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Adverse Events Graded According to NCI-CTCAE Version 5.0 | Grade 5 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Adverse Events Graded According to NCI-CTCAE Version 5.0 | Grade 3 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Adverse Events Graded According to NCI-CTCAE Version 5.0 | Grade 3 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Adverse Events Graded According to NCI-CTCAE Version 5.0 | Grade 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Adverse Events Graded According to NCI-CTCAE Version 5.0 | Grade 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Adverse Events Graded According to NCI-CTCAE Version 5.0 | Grade 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Adverse Events Graded According to NCI-CTCAE Version 5.0 | Grade 5 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Adverse Events Graded According to NCI-CTCAE Version 5.0 | Grade 5 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Adverse Events Graded According to NCI-CTCAE Version 5.0 | Grade 4 | 2 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Adverse Events Graded According to NCI-CTCAE Version 5.0 | Grade 2 | 2 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Adverse Events Graded According to NCI-CTCAE Version 5.0 | Grade 3 | 2 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Adverse Events Graded According to NCI-CTCAE Version 5.0 | Grade 1 | 1 Participants |
Secondary
Phase 2 of Sub-Study B: Number of Participants With Positive Anti-Drug Antibody (ADA) Against Sasanlimab and SEA-TGT
Time frame: Pre-dose on Cycle 1 Day 1 until end of treatment (up to approximately 21 months) (1 cycle= 21 days)
Population: Immunogenicity analysis set included participants who had at least 1 analyzed sasanlimab ADA/NAb sample.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Positive Anti-Drug Antibody (ADA) Against Sasanlimab and SEA-TGT | ADA against SEA-TGT | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Positive Anti-Drug Antibody (ADA) Against Sasanlimab and SEA-TGT | ADA against sasanlimab | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Positive Anti-Drug Antibody (ADA) Against Sasanlimab and SEA-TGT | ADA against sasanlimab | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Positive Anti-Drug Antibody (ADA) Against Sasanlimab and SEA-TGT | ADA against SEA-TGT | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Positive Anti-Drug Antibody (ADA) Against Sasanlimab and SEA-TGT | ADA against sasanlimab | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Positive Anti-Drug Antibody (ADA) Against Sasanlimab and SEA-TGT | ADA against SEA-TGT | 0 Participants |
Secondary
Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0
Chemistry parameters included: ALT increased, ALP increased, AST increased, blood bilirubin increased, chronic kidney disease, creatinine increased, hypercalcemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypokalemia, hypomagnesemia, hyponatremia, lipase increased, serum amylase increased. Number of participants with maximum CTCAE V5.0 grade in chemistry parameters were reported. Grade 0= non-missing lab value that does not meet either of Grade 1 through 4 criteria; Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling.
Time frame: From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment (maximum exposure = 38.66 months; maximum follow-up approximately 39.66 months)
Population: Safety analysis set included all participants who received at least 1 dose of study drug. Here, Number Analyzed signifies number of participants evaluable for the specified rows.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 1 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 4 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 0 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 0 to 0 | 3 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 0 to 0 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 0 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 2 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 2 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 0 to 3 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 0 to 1 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 0 to 0 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 0 to 0 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 1 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 0 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 0 to 1 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 1 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 1 to 0 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 0 to 2 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 4 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 0 to 0 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 3 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 0 to 2 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 2 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 0 to 0 | 3 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 1 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 2 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 0 to 0 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 4 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 4 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 2 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 4 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 1 to 1 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 2 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 2 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 1 to 2 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 0 to 0 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 2 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 0 to 1 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 0 to 3 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 0 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 0 to 3 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 0 to 0 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 0 to 0 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 0 to 0 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 0 to 1 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 3 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 0 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 2 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 0 to 1 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 2 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 2 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 0 to 0 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 0 to 1 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 0 to 3 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 3 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 1 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 4 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 0 to 0 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 0 to 2 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 0 to 1 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 0 to 0 | 3 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 0 to 1 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 0 to 0 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 0 to 0 | 3 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 4 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 4 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 3 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 0 to 0 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 0 to 1 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 0 to 1 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 2 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 1 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 0 to 0 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 1 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 0 to 3 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 1 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 0 to 0 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 0 to 0 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 0 to 0 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 0 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 1 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 1 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 1 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 2 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 0 to 0 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 0 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 2 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 2 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 0 to 0 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 0 to 0 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 4 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 0 to 3 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 0 to 0 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 0 to 3 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 0 to 1 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 4 to 4 | 00 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 0 to 0 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 0 to 0 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 1 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 2 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 2 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 2 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 4 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 4 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 4 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 0 to 0 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 0 to 1 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 2 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 2 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 2 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 3 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 4 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 0 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 0 to 2 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 1 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 1 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 2 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 2 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 3 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 0 to 0 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 1 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 3 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 4 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 1 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 1 to 3 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 2 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 0 to 0 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 0 to 1 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 0 to 0 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 0 to 0 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 0 to 0 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 0 to 0 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 0 to 0 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 0 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 3 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 4 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 4 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 0 to 0 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 0 to 0 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 1 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 1 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 3 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 2 to 1 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 3 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 3 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 3 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 1 to 2 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 0 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 4 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 3 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 1 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 4 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 3 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 0 to 4 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 4 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 2 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 3 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 0 to 0 | 5 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 2 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 2 to 3 | 1 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 0 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 2 to 2 | 1 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 4 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 1 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 1 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 2 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 2 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 0 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 1 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 1 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 0 to 0 | 3 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 2 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 1 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 4 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 0 to 0 | 4 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 4 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 0 to 1 | 1 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 3 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 3 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 4 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 3 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 3 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 3 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 3 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 0 to 0 | 4 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 4 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 3 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 3 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 4 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 3 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 3 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 2 to 4 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 0 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 2 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 3 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 1 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 2 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 3 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 1 to 1 | 1 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 1 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 2 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 1 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 0 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 2 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 1 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 0 to 3 | 1 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 4 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 3 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 4 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 4 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 3 to 2 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 4 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 4 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 2 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 4 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 3 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 4 to 0 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 4 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 3 to 2 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 4 to 1 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 4 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 3 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 1 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 0 to 0 | 7 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 2 to 4 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 4 to 2 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 1 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 2 to 1 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 3 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 1 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 1 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 1 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 1 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 1 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 1 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 1 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 0 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 3 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 0 to 3 | 3 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 0 to 0 | 6 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 3 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 1 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 0 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 3 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 1 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 0 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 3 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 0 to 1 | 4 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 4 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 3 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 3 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 0 to 0 | 6 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 4 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 3 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 2 to 4 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 4 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 3 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 0 to 0 | 7 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 0 to 0 | 6 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 2 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 0 to 1 | 1 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 2 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 4 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 0 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 4 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 0 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 0 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 3 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 4 to 2 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 0 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 3 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 4 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 1 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 2 to 3 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 4 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 3 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 1 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 4 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 3 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 3 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 4 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 2 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 4 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 4 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 2 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 0 to 4 | 1 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 2 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 1 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 2 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 0 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 1 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 1 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 2 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 1 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 1 to 0 | 2 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 4 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 1 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 4 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 2 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 0 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 2 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 2 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 0 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 4 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 2 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 0 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 4 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 3 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 0 to 1 | 2 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 2 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 4 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 0 to 0 | 3 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 4 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 4 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 4 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 1 to 1 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 4 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 2 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 4 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 4 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 2 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 3 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 4 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 2 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 1 to 0 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 0 to 0 | 6 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 2 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 2 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 1 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 2 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 0 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 1 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 1 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 3 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 1 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 1 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 2 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 2 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 4 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 0 to 2 | 2 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 2 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 3 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 1 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 2 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 2 to 0 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 4 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 2 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 2 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 3 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 1 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 0 to 1 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 3 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 1 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 3 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 3 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 1 to 2 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 4 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 4 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 2 to 2 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 4 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 3 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 4 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 4 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 3 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 2 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 4 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 1 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 0 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 0 to 0 | 5 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 1 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 0 to 0 | 6 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 0 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 0 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 3 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 0 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 0 to 0 | 3 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 2 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 0 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 1 to 0 | 1 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 0 to 1 | 1 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 2 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 2 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 2 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 4 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 4 to 1 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 2 to 1 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 3 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 3 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 0 to 2 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 3 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 3 to 1 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 4 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 0 to 0 | 5 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 2 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 1 to 4 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 0 to 1 | 1 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 1 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 3 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 0 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 0 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 0 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 0 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 2 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 1 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 0 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 2 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 2 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 4 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 2 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 2 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 4 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 2 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 2 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 4 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 1 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 2 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 2 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 2 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 2 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 4 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 3 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 3 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 4 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 4 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 4 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 1 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 3 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 4 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 1 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 3 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 3 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 3 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Creatinine increased | Grade 3 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 3 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 3 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 0 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 3 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 3 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 0 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 1 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 3 to 4 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 0 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 1 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 3 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 0 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 1 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 1 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 1 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 2 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 0 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 2 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 2 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 0 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 0 to 1 | 1 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 2 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 0 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 1 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 2 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Serum amylase increased | Grade 0 to 1 | 1 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 4 to 3 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 2 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 4 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 4 to 4 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 3 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 4 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 0 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 4 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 4 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 2 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 4 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 2 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 0 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypercalcemia | Grade 4 to 3 | 00 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 2 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 0 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 1 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 2 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 4 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 1 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 1 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 1 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 1 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 0 to 2 | 2 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 2 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 1 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 0 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 3 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 3 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 3 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 0 to 0 | 4 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 3 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 1 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 1 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 4 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 0 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 4 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 0 to 2 | 1 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 0 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 2 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyperkalemia | Grade 4 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 3 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 2 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 0 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 3 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 0 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 1 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 3 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 0 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 0 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 3 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 0 to 0 | 5 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 0 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 0 to 1 | 4 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 1 to 1 | 1 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 0 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | AST increase | Grade 0 to 0 | 2 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 4 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 0 to 3 | 1 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 4 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 1 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 0 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 3 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 4 to 2 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 1 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 3 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 4 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 1 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 3 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 2 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 1 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 2 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 4 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 1 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 2 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 1 to 2 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 3 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 3 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 1 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 3 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Blood bilirubin increased | Grade 4 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 1 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 1 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALP increased | Grade 1 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 2 to 3 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 0 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 4 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 2 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 4 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 1 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 4 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 1 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 1 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 4 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 2 to 2 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 1 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 3 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 4 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 1 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 3 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypermagnesemia | Grade 2 to 0 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 2 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 3 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 0 to 2 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 3 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 2 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 3 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 2 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 0 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 2 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 3 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 4 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 1 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 1 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | CPK increased | Grade 4 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 1 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 1 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hyponatremia | Grade 0 to 0 | 4 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 0 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 0 to 4 | 1 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 0 to 2 | 1 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 0 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypernatremia | Grade 3 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 0 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 0 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 1 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 3 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 1 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | ALT increased | Grade 0 to 1 | 3 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 2 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 1 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 2 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Lipase increased | Grade 1 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypocalcemia | Grade 2 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 2 to 2 | 1 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 4 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 2 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 2 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 2 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 2 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 3 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 4 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoglycemia | Grade 1 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 3 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 4 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypoalbuminemia | Grade 1 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 3 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 2 to 2 | 1 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 4 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 4 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 1 to 4 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 4 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 3 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypokalemia | Grade 1 to 3 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Chronic kidney disease | Grade 4 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Chemistry Parameter Values Based on CTCAE V5.0 | Hypomagnesemia | Grade 3 to 2 | 0 Participants |
Secondary
Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0
Hematology parameters included: anemia, hemoglobin increased, lymphocyte count decreased, leukocytosis, neutrophil count decreased, platelet count decreased, white blood cell decreased. Number of participants with shift from baseline in hematology parameters by grades as per CTCAE version 5.0 were reported. Grade 0= non-missing lab value that does not meet either of Grade 1 through 4 criteria; Grade 1= mild; Grade 2= moderate; Grade 3= severe and Grade 4= life-threatening or disabling.
Time frame: From the start of study treatment (Cycle1 Day1) up to 30 days after last dose of study treatment (maximum exposure = 38.66 months; maximum follow-up approximately 39.66 months)
Population: Safety analysis set included all participants who received at least 1 dose of study drug.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 0 to 2 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 3 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 0 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 0 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 0 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 0 to 0 | 3 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 1 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 0 to 0 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 2 to 4 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 2 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 3 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 1 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 4 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 1 to 3 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 4 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 4 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 4 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 4 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 0 to 3 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 0 to 0 | 3 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 0 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 0 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 0 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 4 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 0 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 1 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 1 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 1 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 4 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 1 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 4 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 1 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 3 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 1 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 3 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 2 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 0 to 0 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 2 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 2 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 2 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 2 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 0 to 3 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 1 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 2 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 1 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 3 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 4 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 4 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 0 to 0 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 0 to 1 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 0 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 2 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 1 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 0 to 2 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 3 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 2 to 2 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 4 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 2 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 4 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 3 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 4 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 4 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 4 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 4 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 0 to 0 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 4 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 4 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 4 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 0 to 0 | 3 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 4 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 0 to 1 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 1 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 0 to 0 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 0 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 1 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 2 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 3 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 4 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 4 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 4 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 4 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 3 to 2 | 00 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 4 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 4 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 4 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 0 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 0 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 1 to 1 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 1 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 2 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 3 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 4 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 4 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 4 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 4 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 0 to 0 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 0 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 1 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 2 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 3 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 4 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 4 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 4 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 4 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 0 to 0 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 0 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 4 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 0 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 0 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 1 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 1 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 1 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 1 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 1 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 2 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 2 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 2 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 2 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 2 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 3 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 3 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 3 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 4 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 4 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 0 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 0 to 3 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 1 to 3 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 1 to 2 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 1 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 4 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 2 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 0 to 4 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 3 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 1 to 0 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 1 to 1 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 4 to 2 | NA Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 0 to 0 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 0 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 0 to 0 | 2 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 1 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 4 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 0 to 0 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 0 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 0 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 0 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 1 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 1 to 1 | 1 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 1 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 1 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 1 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 2 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 2 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 2 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 2 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 2 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 3 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 3 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 3 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 3 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 3 to 4 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 4 to 0 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 4 to 1 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 4 to 2 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 4 to 3 | 0 Participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 4 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 0 to 1 | 2 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 4 to 1 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 3 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 0 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 1 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 0 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 0 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 3 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 0 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 0 to 1 | 1 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 4 to 0 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 3 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 0 to 0 | 6 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 3 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 4 to 2 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 4 to 3 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 4 to 4 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 4 to 4 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 0 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 0 to 0 | 7 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 3 to 4 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 0 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 4 to 3 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 3 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 0 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 0 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 1 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 4 to 2 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 1 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 1 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 3 to 1 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 1 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 4 to 1 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 4 to 0 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 4 to 4 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 2 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 3 to 4 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 1 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 2 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 2 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 3 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 4 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 3 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 3 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 2 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 1 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 3 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 3 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 3 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 3 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 2 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 3 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 2 to 4 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 2 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 2 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 4 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 2 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 1 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 0 to 0 | 6 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 2 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 1 to 1 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 0 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 1 to 4 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 4 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 0 to 2 | 1 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 1 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 0 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 1 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 1 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 0 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 1 to 1 | 1 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 1 to 0 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 1 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 1 to 0 | 1 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 3 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 1 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 0 to 4 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 2 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 1 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 0 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 0 to 4 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 1 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 0 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 2 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 1 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 0 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 2 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 2 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 0 to 0 | 5 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 0 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 2 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 4 to 1 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 4 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 2 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 2 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 4 to 0 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 0 to 1 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 2 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Anemia | Grade 2 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 4 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 3 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 2 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 2 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 3 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 4 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 2 to 2 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 4 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 2 to 3 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 2 to 1 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 3 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 2 to 4 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 2 to 0 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 4 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 3 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 1 to 4 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 2 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 3 to 1 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 3 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 3 to 2 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 1 to 3 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 4 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 3 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 1 to 2 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 2 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 3 to 4 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 1 to 1 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 3 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 1 to 0 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 3 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 4 to 2 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 4 to 3 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 0 to 4 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 1 to 2 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 0 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 0 to 2 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 3 to 4 | 1 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 0 to 0 | 3 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 0 to 1 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 4 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 0 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Leukocytosis | Grade 0 to 0 | 7 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 0 to 2 | 2 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 4 to 4 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 3 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 4 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 0 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 4 to 3 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 4 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 0 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 4 to 2 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 2 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 1 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 4 to 1 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 3 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 1 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 4 to 0 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 1 to 3 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 3 to 4 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 4 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 1 to 4 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 1 to 3 | 1 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 3 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 2 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 1 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 3 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 2 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 3 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 4 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 2 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 3 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 1 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 3 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 4 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 3 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 2 to 4 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Platelet count decreased | Grade 4 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 1 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 2 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 2 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 3 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 4 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 2 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 4 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 2 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 4 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | White blood Cell decreased | Grade 0 to 0 | 5 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 2 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 1 to 4 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 1 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Neutrophil count decrease | Grade 0 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 2 to 1 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 4 to 4 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 0 to 0 | 7 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 1 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 1 to 1 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count decreased | Grade 3 to 2 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 0 to 3 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 1 to 0 | 0 Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Lymphocyte count increased | Grade 2 to 4 | NA Participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Number of Participants With Shift From Baseline in Hematology Parameter Values Based on CTCAE V5.0 | Hemoglobin increased | Grade 0 to 4 | NA Participants |
Secondary
Phase 2 of Sub-Study B: Objective Response Rate by PD-L1 Expression in Available Tumor Tissue
ORR was defined as percentage of participants with confirmed CR or PR according to RECIST v1.1 based on investigator assessment, from the date of first CR or PR until the date of the first documentation of disease progression (PD), death, or start of new anticancer therapy. CR was defined as complete disappearance of all target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 millimeter \[mm\]). PR was defined as greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions. PD was defined as 20% increase in sum of diameters of target measurable lesions above smallest sum observed (over baseline if no decrease in the sum was observed during therapy), with a minimum absolute increase of 5 mm.
Time frame: From the date of first CR or PR until the date of the first documentation of PD, death, or start of new anticancer therapy (maximum of 21 months)
Population: Full analysis set included all participants who received at least 1 dose of study drug.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Objective Response Rate by PD-L1 Expression in Available Tumor Tissue | 33.3 Percentage of participants |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Objective Response Rate by PD-L1 Expression in Available Tumor Tissue | 0 Percentage of participants |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Objective Response Rate by PD-L1 Expression in Available Tumor Tissue | 14.3 Percentage of participants |
Secondary
Phase 2 of Sub-Study B: Overall Survival (OS)
OS is defined as the time from the date of first dose of study treatment to the date of death due to any cause. Participants last known to be alive were planned to be censored at the date of last contact.
Time frame: From the date of first dose of study treatment to the date of death due to any cause or censoring date, whichever occurred first (maximum of 21 months)
Population: Full analysis set included all participants who received at least 1 dose of study drug.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Overall Survival (OS) | NA Months |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Overall Survival (OS) | NA Months |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Overall Survival (OS) | 4.0 Months |
Secondary
Phase 2 of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of Axitinib
Time frame: Pre-dose on Cycle 1 Day 1 and Day 8; pre-dose on Cycle 5 Day 1 and Day 8 (1 cycle= 21 days)
Population: PK parameter analysis set was subset of safety analysis set (participants who received at least 1 dose of study drug) with participants who had at least 1 of PK parameters of interest for measured analytes related to study drug. Here, 'Number of Participants Analyzed' signifies participants evaluable for this outcome measure and 'Number Analyzed' signifies participants evaluable at specified timepoints.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of Axitinib | Cycle 1 Day 8 | 39.50 Nanograms per milliliter | — |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of Axitinib | Cycle 1 Day 8 | 2.360 Nanograms per milliliter | — |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of Axitinib | Cycle 1 Day 8 | 2.708 Nanograms per milliliter | Geometric Coefficient of Variation 132 |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of Axitinib | Cycle 5 Day 1 | 3.630 Nanograms per milliliter | — |
| Unknown | Phase 2 of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of Axitinib | Cycle 1 Day 1 | — Nanograms per milliliter | — |
| Unknown | Phase 2 of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of Axitinib | Cycle 5 Day 8 | — Nanograms per milliliter | — |
Secondary
Phase 2 of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of Sasanlimab
Time frame: Cycle 1: pre-dose on Day 1, Cycle 5: pre-dose on Day 1 (1 cycle= 21 days)
Population: PK parameter analysis set: subset of safety analysis set (participants who received at least 1 dose of study drug) with participants who had at least 1 of PK parameters of interest for measured analytes related to study drug. 'Number of Participants Analyzed': participants with evaluable data for this outcome measure and 'Number Analyzed': participants evaluable at specified time points. This outcome measure was not applicable for participants of ''Phase 2 of SSB: 1L NSCLC / PD-L1: TPS 1-49%''
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of Sasanlimab | Cycle 5 | 30400 Nanograms per milliliter |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of Sasanlimab | Cycle 1 | 87.01 Nanograms per milliliter |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of Sasanlimab | Cycle 5 | 20000 Nanograms per milliliter |
Secondary
Phase 2 of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of SEA-TGT
Time frame: Pre-dose on Cycle 1 Day 1; pre-dose on Cycle 5 Day 1 (1 cycle= 21 days)
Population: PK parameter analysis set: subset of safety analysis set (participants who received at least 1 dose of study drug) with participants who had at least 1 of PK parameters of interest for measured analytes related to study drug. Here 'Number of Participants Analyzed': participants evaluable for this outcome measure and 'Number Analyzed': participants evaluable at specified time points. This outcome measure was not applicable for participants of ''Phase 2 of SSB: 1L NSCLC / PD-L1: TPS 1-49%''
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of SEA-TGT | Cycle 5 | 5770 Nanograms per milliliter |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of SEA-TGT | Cycle 1 | 55.00 Nanograms per milliliter |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of SEA-TGT | Cycle 1 | 24.47 Nanograms per milliliter |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Pre-dose Concentration During Multiple Dosing (Ctrough) of SEA-TGT | Cycle 5 | 8490 Nanograms per milliliter |
Secondary
Phase 2 of Sub-Study B: Progression-Free Survival (PFS)
PFS is defined as the time from the date of first dose of study treatment to the date of first documentation of PD or death due to any cause, whichever occurred first. PD=20% increase in sum of diameters of target measurable lesions above smallest sum observed (over baseline if no decrease in sum was observed during therapy), with a minimum absolute increase of 5 mm.
Time frame: From the date of first dose of study treatment to the date of first documentation of PD or death due to any cause, whichever occurred first (maximum of 21 months)
Population: Full analysis set included all participants who received at least 1 dose of study drug.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Progression-Free Survival (PFS) | 4.2 Months |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Progression-Free Survival (PFS) | NA Months |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Progression-Free Survival (PFS) | 3.4 Months |
Secondary
Phase 2 of Sub-Study B: Time to Tumor Response (TTR)
TTR is defined for participants with confirmed OR as the time from the date of first dose of study treatment to the date of first documentation of objective response (CR or PR) which was subsequently confirmed. CR=complete disappearance of all target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis \<10 mm). PR=greater than or equal to 30% decrease under baseline of the sum of diameters of all target measurable lesions.
Time frame: From the date of first dose of study treatment to the date of first documentation of objective response (CR or PR) (maximum of 21 months)
Population: Full analysis set included all participants who received at least 1 dose of study drug. Here, Overall Number of Participants Analyzed signifies participants evaluable for this outcome measure.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (300mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Time to Tumor Response (TTR) | 4.1 Months |
| Phase 1b of SSA: Sasanlimab (300mg) + Encorafenib (450mg) + Binimetinib (45mg) | Phase 2 of Sub-Study B: Time to Tumor Response (TTR) | 1.3 Months |
| Phase 2 of SSB: 2/3L NSCLC / PD-L1: TPS >=1% (Sasanlimab (225mg)+Axitinib (5mg)+SEA-TGT (1mg/kg) | Phase 2 of Sub-Study B: Time to Tumor Response (TTR) | 1.4 Months |